

African Americans

PRESENTED BY AMERICA'S PHARMACEUTICAL COMPANIES


Nearly 700 Medicines in the Pipeline Offer Hope for Closing the Health Gap for African Americans

America's pharmaceutical research companies are developing 691 medicines for diseases that disproportionately afflict African Americans or diseases that are among the top 10 causes of death among African Americans. These medicines will help close the health disparity between African Americans and the rest of the population. The potential medicines are either in clinical trials or awaiting approval by the Food and Drug Administration.

The medicines in development include:

- 229 medicines for cancers that disproportionately affect African Americans. According to the American Cancer Society, African Americans have the highest mortality rate of any racial and ethnic group for all cancers combined. They have higher death rates for colorectal, male lung, female breast, and prostate cancers. In fact, African American men may have the highest incidence rate of prostate cancer in the world, and their death rate is twice as high as that of white American men. The medicines in the pipeline target cancers of the breast, cervix, colon/rectum, lung, prostate, and uterus.
- 114 medicines designed to treat cardiovascular disease, including coronary artery disease, heart attack, heart failure, and hypertension. According to the American Heart Association, African Americans have the highest prevalence rate of high blood pressure in the world.
- 95 medicines in development for diabetes. According to the American Diabetes Association, African Americans are nearly two times more likely to have diabetes compared with whites.
- 77 medicines for respiratory disorders, including asthma. According to the American Lung Association, African Americans have the highest asthma rate of any other racial and ethnic group. They are also three times more likely to die from asthma than whites.
- 67 medicines that target HIV infection. Although the overall estimated numbers of new HIV infections are decreasing, African Americans accounted for 49 percent of cases of HIV infection diagnosed in 2005,

MEDICINES IN DEVELOPMENT FOR AFRICAN AMERICANS*



*Some medicines are listed in more than one category.

according to the U.S. Centers for Disease Control and Prevention.

Other medicines in development tackle kidney disease, glaucoma, obesity, and sickle cell disease.

The reasons for the health disparity between African Americans and other Americans are complex and not completely understood. Lack of access to medical care is thought to play a role. African Americans, and all Americans, should have timely access to the medicines their physicians believe would work best for them.

These 691 medicines in development by America's pharmaceutical research companies may one day help bridge the health gap and increase the likelihood that all Americans will share in the benefits of medical progress.

Billy Tauzin
President and CEO
PhRMA

Medicines in Development for Major Diseases Affecting African Americans

CANCER

Product Name	Company	Indication	Development Status*
1018 ISS	Dynavax Technologies <i>Berkeley, CA</i>	colorectal	Phase I (510) 848-5100
A-007	Tigris Pharmaceuticals <i>Bonita Springs, FL</i>	cervical intraepithelial neoplasia	Phase II (239) 444-5400
ABI-007	Abraxis BioScience <i>Los Angeles, CA</i> AstraZeneca <i>Wilmington, DE</i>	cervical (see also heart disease)	Phase I (310) 883-1300 (800) 236-9933
ABI-008	Abraxis BioScience <i>Los Angeles, CA</i>	prostate	Phase I (310) 883-1300
abiraterone acetate	Cougar Biotechnology <i>Los Angeles, CA</i>	prostate	Phase I (310) 943-8040
ABT 510	Abbott Laboratories <i>Abbott Park, IL</i>	lung	Phase II (847) 937-6100
ABT 751	Abbott Laboratories <i>Abbott Park, IL</i>	breast, colorectal, non-small-cell lung (NSCLC)	Phase II (847) 937-6100
Actigall [®] ursodeoxycholic acid	Watson Pharmaceutical <i>Corona, CA</i>	colorectal	Phase II (800) 249-5499
Actimid [™]	Celgene <i>Summit, NJ</i>	prostate	Phase II (908) 673-9000
AE37	Antigen Express <i>Worcester, MA</i>	breast	Phase II (508) 852-8783
		prostate	Phase I (508) 852-8783
afibercept (VEGF-trap)	Regeneron Pharmaceuticals <i>Tarrytown, NY</i> sanofi-aventis <i>Bridgewater, NJ</i>	breast, colorectal, NSCLC	Phase II (914) 345-7400 (800) 633-1610
AGS-PSCA	Agensys <i>Santa Monica, CA</i> Merck <i>Whitehouse Station, NJ</i>	prostate	Phase I (310) 820-8029 (800) 672-6372
Alimta [®] pemetrexed	Eli Lilly <i>Indianapolis, IN</i>	colorectal, lung, small-cell lung (SCLC)	Phase III (800) 545-5979
		breast	Phase II (800) 545-5979

* For more information about a specific medicine in this report, please call the telephone number listed.

CANCER

Product Name	Company	Indication	Development Status
alitreinoin oral	Ligand Pharmaceuticals <i>San Diego, CA</i>	lung cancer prevention	Phase II (858) 550-7500
ALVAC-CEA B7.1 (cancer vaccine)	Therion Biologics <i>Cambridge, MA</i>	colorectal	Phase II (617) 475-7500
amolmogene (cervical cancer DNA vaccine)	MGI Pharma Biologics <i>Bloomington, MN</i>	cervical dysplasia	Phase II (952) 346-4700
amonafide	ChemGenex Pharmaceuticals <i>Menlo Park, CA</i>	breast, prostate	Phase II (650) 474-9800
Amplimexon® imexon	AmpliMed <i>Tucson, AZ</i>	breast, lung, prostate	Phase I (520) 529-1000
amrubicin	Pharmion <i>Boulder, CO</i>	NSCLC, SCLC	Phase II (720) 564-9100
anticancer MAb A33	Life Science Pharmaceuticals <i>Greenwich, CT</i>	colorectal	Phase I (203) 422-6500
anti-KSA cancer vaccine	IDM Pharma <i>Irvine, CA</i>	colorectal	Phase I (949) 470-4751
antineoplaston A10 (injection)	Burzynski Research Institute <i>Houston, TX</i>	prostate	Phase II (713) 335-5697
antineoplaston A10 (oral)	Burzynski Research Institute <i>Houston, TX</i>	breast, colorectal	Phase II (713) 335-5697
antineoplaston AS2-1 (injection)	Burzynski Research Institute <i>Houston, TX</i>	prostate	Phase II (713) 335-5697
antineoplaston AS2-1 (oral)	Burzynski Research Institute <i>Houston, TX</i>	breast, colorectal (see also infectious diseases)	Phase II (713) 335-5697
anti-PEM MAb	Somanta Pharmaceuticals <i>Irvine, CA</i>	breast	Phase I (949) 477-8090
ANX-510	Adventrx Pharmaceuticals <i>San Diego, CA</i>	colorectal	Phase III (858) 552-0866
		breast	Phase II (858) 552-0866
ANX-530	Adventrx Pharmaceuticals <i>San Diego, CA</i>	breast, NSCLC	Phase I (858) 552-0866
AP23573	ARIAD Pharmaceuticals <i>Cambridge, MA</i> Merck <i>Whitehouse Station, NJ</i>	prostate	Phase II (617) 494-0400 (800) 672-6372
		breast	Phase I (617) 494-0400 (800) 672-6372

CANCER

Product Name	Company	Indication	Development Status
Aromasin® exemestane	Pfizer <i>New York, NY</i>	breast cancer prevention	Phase III (860) 732-5156
arzoxifene (next generation SERM)	Eli Lilly <i>Indianapolis, IN</i>	breast cancer treatment	Phase III (800) 545-5979
		breast cancer prevention	Phase II (800) 545-5979
AS-1402 (MAb)	Antisoma <i>London, England</i>	breast	Phase I
AT-101	Ascenta Therapeutics <i>San Diego, CA</i>	prostate	Phase II (858) 436-1200
atamestane	Intarcia Therapeutics <i>Emeryville, CA</i> Bayer HealthCare Pharmaceuticals <i>Wayne, NJ</i>	breast	Phase III (510) 652-2600 (888) 84-BAYER
ATN-224	Attenuon <i>San Diego, CA</i>	prostate	Phase II (858) 720-8797
Avastin® bevacizumab	Genentech <i>South San Francisco, CA</i>	breast	application submitted (650) 225-1000
		prostate	Phase III (650) 225-1000
		SCLC	Phase II (650) 225-1000
Avodart® dutasteride	GlaxoSmithKline <i>Philadelphia, PA</i> <i>Rsch. Triangle Park, NC</i>	prostate cancer prevention, prostatic intraepithelial neoplasia	Phase III (888) 825-5249
axitinib	Pfizer <i>New York, NY</i>	NSCLC	Phase II (860) 732-5156
		breast, colorectal	Phase I (860) 732-5156
AZD-4054	AstraZeneca <i>Wilmington, DE</i>	prostate	Phase I/II (800) 236-9933
belinostat	CuraGen <i>Branford, CT</i>	colorectal	Phase I (888) 436-6642
benzylguanine (06-BG)	Keryx Biopharmaceuticals <i>New York, NY</i>	colorectal	Phase I (212) 531-5965
bleomycin (electrical pulse delivery)	Inovio Biomedical <i>San Diego, CA</i>	breast	Phase I (877) 446-6846
BMS-641988 (androgen receptor antagonist)	Bristol-Myers Squibb <i>Princeton, NJ</i>	prostate	Phase I (212) 546-4000

CANCER

Product Name	Company	Indication	Development Status
BMS-663513 (anti-CD 137 antibody)	Bristol-Myers Squibb <i>Princeton, NJ</i>	NSCLC	Phase I (212) 546-4000
bosutinib	Wyeth Pharmaceuticals <i>Collegeville, PA</i>	breast	Phase I (800) 934-5556
BZL-101	Bionovo <i>Emeryville, CA</i>	breast	Phase I (510) 601-2000
CA4P (combretastatin A4 phosphate)	OXiGENE <i>Waltham, MA</i>	breast, lung	Phase II (781) 547-5900
Camptosar® irinotecan	Pfizer <i>New York, NY</i>	cervical, lung	application submitted (860) 732-5156
		prostate	Phase II (860) 732-5156
cancer vaccine	Centocor <i>Horsham, PA</i>	colorectal	Phase I (610) 651-6000
cancer vaccine	Genzyme <i>Cambridge, MA</i>	breast	Phase II (617) 252-7500
canertinib	Pfizer <i>New York, NY</i>	breast, lung	Phase I (860) 732-5156
CDB-2914	HRA Pharma <i>New York, NY</i>	uterine leiomyoma	Phase II (212) 679-2945
CDX-1307	Celldex Therapeutics <i>Phillipsburg, NJ</i>	breast, colorectal	Phase I (908) 454-7120
Celebrex® celecoxib	Pfizer <i>New York, NY</i>	colorectal	Phase III (860) 732-5156
		NSCLC, prostate	Phase II (860) 732-5156
		cervical dysplasia	in clinical trials (860) 732-5156
CGC-11047	Cellgate <i>Redwood City, CA</i>	prostate	Phase II (650) 610-7800
Cloretazine® VNP 40101M	Vion Pharmaceuticals <i>New Haven, CT</i>	SCLC	Phase II (203) 498-4210
Collidem™	IDM Pharma <i>Irvine, CA</i>	colorectal	Phase I (949) 470-4751
Corlux® mifepristone	Corcept Therapeutics <i>Menlo Park, CA</i>	prostate (see also obesity)	Phase II (650) 327-3270
		uterine leiomyoma	in clinical trials (650) 327-3270
CP-751871	Pfizer <i>New York, NY</i>	NSCLC, prostate	Phase II (860) 732-5156

CANCER

Product Name	Company	Indication	Development Status
CT-2106	Cell Therapeutics <i>Seattle, WA</i>	colorectal	Phase I (800) 215-CELL
CYT-424	Cytogen <i>Princeton, NJ</i>	prostate	Phase II (800) 833-3533
CYT-500	Cytogen <i>Princeton, NJ</i>	prostate	Phase I (800) 833-3533
Davanat [®] polysaccharide polymer	Pro-Pharmaceuticals <i>Newton, MA</i>	colorectal	Phase II (617) 559-0033
degarelix	Ferring Pharmaceuticals <i>Parsippany, NJ</i>	prostate	Phase III (973) 796-1600
diflomotecan	Ipsen <i>Milford, MA</i>	SCLC	Phase II (508) 478-8900
DMXAA	Antisoma <i>London, England</i> Novartis Pharmaceuticals <i>East Hanover, NJ</i>	prostate	Phase II (888) NOW-NOVA
DN-101	Novacea <i>South San Francisco, CA</i> Schering-Plough <i>Kenilworth, NJ</i>	prostate	Phase III (650) 228-1800
		NSCLC	Phase III (650) 228-1800
Doxil [®] doxorubicin liposomal	Johnson & Johnson Pharmaceutical Research & Development <i>Raritan, NJ</i>	breast	Phase III (800) 817-5286
		NSCLC, prostate	Phase II (800) 817-5286
doxorubicin inhaled	Zivena <i>Columbus, OH</i>	lung	Phase II
E75 cancer vaccine	Aphera <i>Scottsdale, AZ</i>	breast	Phase II (480) 882-8841
		prostate	Phase I (480) 882-8841
edotecarin	Merck <i>Whitehouse Station, NJ</i>	colorectal	Phase III (800) 672-6372
enzastaurin	Eli Lilly <i>Indianapolis, IN</i>	breast, NSCLC	Phase II (800) 545-5979
EP-2101	IDM Pharma <i>Irvine, CA</i>	NSCLC	Phase II (949) 470-4751
		colorectal	Phase I (949) 470-4751
Erbix [®] cetuximab	Bristol-Myers Squibb <i>Princeton, NJ</i> Imclone Systems <i>Somerville, NJ</i>	colorectal, lung	in clinical trials (212) 546-4000

CANCER

Product Name	Company	Indication	Development Status
eribulin (E7389)	Eisai <i>Ridgefield Park, NJ</i>	breast	Phase III (888) 274-2378
		NSCLC, prostate	Phase II (888) 274-2378
Evista [®] raloxifene	Eli Lilly <i>Indianapolis, IN</i>	breast cancer prevention	application submitted (800) 545-5979
Fareston [®] toremifene	GTx <i>Memphis, TN</i>	prostate cancer prevention, prostatic intraepithelial neoplasia	Phase III (901) 523-9700
finasteride	Merck <i>Whitehouse Station, NJ</i>	prostate cancer prevention	Phase III (800) 672-6372
		prostate	Phase II (800) 672-6372
Flurizan [™] tarenflurbil	Myriad Genetics <i>Salt Lake City, UT</i>	prostate	Phase II (801) 584-3600
formestane topical cream	Medical Discoveries <i>Salt Lake City, UT</i>	breast	in clinical trials (877) 633-4201
GCS-100	GlycoGenesis <i>Boston, MA</i>	colorectal, prostate	Phase II (617) 422-0674
Gemzar [®] gemcitabine	Eli Lilly <i>Indianapolis, IN</i>	colorectal, SCLC	Phase II (800) 545-5979
Genasense [®] oblimersen	Genta <i>Berkeley Heights, NJ</i>	breast	Phase II (908) 286-9800
Gleevec [®] imatinib	Novartis Pharmaceuticals <i>East Hanover, NJ</i>	prostate	Phase II (888) NOW-NOVA
glufosfamide	Threshold Pharmaceuticals <i>Redwood City, CA</i>	breast, SCLC	Phase II (650) 474-8200
GRNVAC1	Argos Therapeutics <i>Durham, NC</i>	prostate	Phase I (919) 287-6300
	Geron <i>Menlo Park, CA</i>		(650) 473-7700
GTI-2040	Lorus Therapeutics <i>Toronto, ON</i>	breast, colorectal	Phase II (416) 798-1200
GVAX [®] Prostate cancer immunotherapy	Cell Genesys <i>South San Francisco, CA</i>	prostate	Phase III (650) 266-3000
Herceptin [®] trastuzumab	Genentech <i>South San Francisco, CA</i>	colorectal, prostate	Phase II (650) 225-1000
HKI-272	Wyeth Pharmaceuticals <i>Collegeville, PA</i>	breast, NSCLC	Phase II (800) 934-5556
huN901-DM1 antibody	ImmunoGen <i>Cambridge, MA</i>	SCLC	Phase II (617) 995-2500

CANCER

Product Name	Company	Indication	Development Status
Hycamtin® topotecan	GlaxoSmithKline Philadelphia, PA Rsch. Triangle Park, NC	SCLC (second-line therapy)	application submitted (888) 825-5249
		NSCLC	Phase III (888) 825-5249
HyperAcute® Prostate prostate cancer vaccine	NewLink Genetics Ames, IA	prostate	Phase I (515) 296-5555
idronoxil	Marshall Edwards North Ryde, Australia	cervical	Phase II
indisulam (E7070)	Eisai Ridgefield Park, NJ	breast	Phase II (888) 274-2378
INGN-225 cancer vaccine	Introgen Therapeutics Austin, TX	breast, SCLC	Phase I (512) 708-9310
INOC002	Avantogen Oncology Los Angeles, CA	colorectal	Phase II (310) 552-2001
INSM-18	Insmad Richmond, VA	prostate	Phase I (804) 565-3000
interleukin-21	ZymoGenetics Seattle, WA	colorectal	Phase I (800) 775-6686
IntraDose-CDDP™	Novartis Pharmaceuticals East Hanover, NJ	breast, lung	Phase III (888) NOW-NOVA
Iressa® gefitinib	AstraZeneca Wilmington, DE	breast	Phase II (800) 236-9933
irinotecan/ floxuridine fixed-dose combination	Celator Pharmaceuticals Princeton, NJ	colorectal	Phase II (609) 243-0123
irofulven (MGI-114)	MGI Pharma Bloomington, MN	breast, prostate	Phase II (800) 562-0679
		colorectal	Phase I (800) 562-0679
ispinesib	Cytokinetics South San Francisco, CA	breast, colorectal, NSCLC, prostate	Phase II (650) 624-3000
ixabepilone (epothilone)	Bristol-Myers Squibb Princeton, NJ	metastatic breast	application submitted (212) 546-4000
izonsteride	Eli Lilly Indianapolis, IN	prostate	Phase I (800) 545-5979
L-377202	Merck Whitehouse Station, NJ	prostate	Phase I (800) 672-6372
L-651582	Merck Whitehouse Station, NJ	prostate	Phase II (800) 672-6372

CANCER

Product Name	Company	Indication	Development Status
larotaxel (XRP9881)	sanofi-aventis <i>Bridgewater, NJ</i>	breast	Phase III (800) 633-1610
LBH-589	Novartis Pharmaceuticals <i>East Hanover, NJ</i>	prostate	Phase I (888) NOW-NOVA
LE-SN38	NeoPharm <i>Waukegan, IL</i>	colorectal	Phase II (847) 887-0800
Leukine® sargramostim	Bayer HealthCare Pharmaceuticals <i>Wayne, PA</i>	prostate (see also infectious diseases)	Phase I (888) 842-2937
LeuproMaxx™ leuprorelin depot	Teva Parenteral Medicines <i>Irvine, CA</i>	prostate, uterine leiomyoma	Phase II (949) 455-4700
leuprorelin inhalation	Nektar Therapeutics <i>San Carlos, CA</i>	prostate	Phase I (650) 631-3100
Levulan® PD aminolevulinic acid	DUSA Pharmaceuticals <i>Wilmington, DE</i>	cervical intraepithelial neoplasia	Phase II (978) 657-7500
		colorectal, lung	in clinical trials (978) 657-7500
liposome encapsulated doxorubicin	NeoPharm <i>Waukegan, IL</i>	breast, prostate	Phase III (847) 887-0800
Lymphoseek™	Neoprobe <i>Dublin, OH</i>	breast	Phase II (800) 793-0079
mage-A3 (recombinant vaccine)	GlaxoSmithKline <i>Philadelphia, PA</i> <i>Rsch. Triangle Park, NC</i>	treatment of NSCLC	Phase II (888) 825-5249
matuzumab	Takeda Pharmaceuticals North America <i>Deerfield, IL</i>	colorectal, NSCLC	Phase II (224) 554-6500
mepacrine	Cleveland BioLabs <i>Cleveland, OH</i>	prostate	Phase II (216) 229-2251
milataxel	Taxolog <i>Fairfield, NJ</i>	breast, colorectal, NSCLC	Phase II (866) TAXOLOG
MK-0429	Merck <i>Whitehouse Station, NJ</i>	prostate	Phase I (800) 672-6372
MK-0457 (VX-680)	Merck <i>Whitehouse Station, NJ</i> Vertex Pharmaceuticals <i>Cambridge, MA</i>	colorectal, NSCLC	Phase II (800) 672-6372 (617) 444-6100
MK-0752	Merck <i>Whitehouse Station, NJ</i>	advanced breast	Phase I (800) 672-6372
MKC-1	EntreMed <i>Rockville, MD</i>	breast, NSCLC	Phase II (240) 864-2600

CANCER

Product Name	Company	Indication	Development Status
Mobista™ FLT-3 ligand	Amgen <i>Thousand Oaks, CA</i>	prostate	Phase II (805) 447-1000
Modrenal® trilostane	Bioenvision <i>New York, NY</i>	prostate	Phase II (212) 750-6700
		breast	in clinical trials (212) 750-6700
motesanib disphosphate (AMG 706)	Amgen <i>Thousand Oaks, CA</i>	breast, NSCLC	Phase II (805) 447-1000
		colorectal	Phase I (805) 447-1000
MUC-1 cancer vaccine	Avantogen <i>Los Angeles, CA</i>	breast, prostate	Phase I (310) 552-2001
Multikine® leukocyte interleukin	CEL-SCI <i>Vienna, VA</i>	cervical, cervical dysplasia	Phase II (703) 506-9460
MVA-BN®-HER2 (vaccine)	BN ImmunoTherapeutics <i>Mountain View, CA</i>	breast	Phase I (650) 681-4660
Myocet™ doxorubicin liposomal	Sopherion Therapeutics <i>Princeton, NJ</i>	breast	Phase III (609) 986-2021
NBI-42902	Neurocrine Biosciences <i>San Diego, CA</i>	breast, prostate, uterine leiomyoma	Phase I (858) 617-7600
Neuvenge™ lapuleucel-T	Dendreon <i>Seattle, WA</i>	breast, colorectal	Phase I (206) 256-4545
Norelin™ prostate cancer vaccine	YM Biosciences USA <i>Wayne, PA</i>	prostate	Phase II (610) 560-0600
NOV-002	Novelos Therapeutics <i>Newton, MA</i>	NSCLC	Phase III (617) 244-1616
		breast	Phase II (617) 244-1616
Omnitarg™ pertuzumab	Genentech <i>South San Francisco, CA</i>	breast	Phase III (650) 224-1000
Oncolar® octreotide	Novartis Pharmaceuticals <i>East Hanover, NJ</i>	breast	Phase III (888) NOW-NOVA
Oporia™ lasofoxifene	Ligand Pharmaceuticals <i>San Diego, CA</i> Pfizer <i>New York, NY</i>	breast cancer prevention	Phase III (858) 550-7500 (860) 732-5156
OPT-22	Optimer Pharmaceuticals <i>San Diego, CA</i>	breast	Phase I (858) 909-0736

CANCER

Product Name	Company	Indication	Development Status
Orathecin™ rubitecan	SuperGen <i>Dublin, CA</i>	breast, lung	Phase II (925) 560-0100
		colorectal, prostate	Phase I (925) 560-0100
ozarelix	Spectrum Pharmaceuticals <i>Irvine, CA</i>	prostate	Phase I (949) 788-6700
P501 (recombinant vaccine)	GlaxoSmithKline <i>Philadelphia, PA</i> <i>Rsch. Triangle Park, NC</i>	prostate cancer treatment	Phase I (888) 825-5249
P-2045	Xanthus Pharmaceuticals <i>Cambridge, MA</i>	NSCLC, SCLC	Phase I (617) 225-0522
Panzem® NCD 2-methoxyestradiol	EntreMed <i>Rockville, MD</i>	prostate	Phase II (240) 864-2600
		breast	Phase I (240) 864-2600
patupilone	Novartis Pharmaceuticals <i>East Hanover, NJ</i>	breast, NSCLC	Phase II (888) NOW-NOVA
		colorectal	Phase I (888) NOW-NOVA
pazopanib	GlaxoSmithKline <i>Philadelphia, PA</i> <i>Rsch. Triangle Park, NC</i>	breast, cervical, NSCLC	Phase II (888) 825-5249
pazopanib and Tykerb® combination	GlaxoSmithKline <i>Philadelphia, PA</i> <i>Rsch. Triangle Park, NC</i>	breast	Phase II (888) 825-5249
PD-325901	Pfizer <i>New York, NY</i>	NSCLC	Phase II (860) 732-5156
		breast, colorectal	Phase I (860) 732-5156
pelitinib	Wyeth Pharmaceuticals <i>Collegeville, PA</i>	colorectal, NSCLC	Phase II (800) 934-5556
pelitrexol	Pfizer <i>New York, NY</i>	colorectal, NSCLC	Phase II (860) 732-5156
perifosine (KRX-0401)	Keryx Biopharmaceuticals <i>New York, NY</i>	breast, prostate	Phase II (212) 531-5965
		NSCLC	Phase I (212) 531-5965
PF-3512676	Pfizer <i>New York, NY</i>	breast	Phase I (860) 732-5156

CANCER

Product Name	Company	Indication	Development Status
picoplatin	Poniard Pharmaceuticals <i>South San Francisco, CA</i>	SCLC	Phase II (650) 583-3774
		colorectal, prostate	Phase I (650) 583-3774
plitidepsin	PharmaMar USA <i>Cambridge, MA</i>	prostate, SCLC	Phase II (617) 621-5300
Proellex™	Repros Therapeutics <i>The Woodlands, TX</i>	uterine leiomyoma	Phase II (281) 719-3400
ProstAtak™ cancer gene therapy	Advantagene <i>Encinitas, CA</i>	prostate	Phase II (760) 493-8981
Prostvac-VF® prostate cancer vaccine	Therion Biologics <i>Cambridge, MA</i>	prostate	Phase II (617) 475-7500
Provenge® sipuleucel-T	Dendreon <i>Seattle, WA</i>	prostate	application submitted/ Phase III (206) 256-4545
PRX-302	Protox Therapeutics <i>Vancouver, BC</i>	prostate	Phase I (604) 688-0199
PSMA cancer vaccine	PSMA Development <i>Tarrytown, NY</i>	prostate	Phase I (914) 789-2800
PV-701	Wellstat Biologics <i>Gaithersburg, MD</i>	cervical, colorectal	Phase II (240) 631-2500
R-851	Takeda Pharmaceuticals North America <i>Deerfield, IL</i>	cervical dysplasia	Phase II (224) 554-2000
RC-8800	Sapphire Therapeutics <i>Bridgewater, NJ</i>	prostate	Phase I (908) 231-1435
Recentin™ cediranib	AstraZeneca <i>Wilmington, DE</i>	breast	Phase II (800) 236-9933
rhizoxin	Astellas Pharma <i>Deerfield, IL</i>	breast, NSCLC	Phase II (800) 695-4321
RM1812	Royalmount Pharmaceuticals <i>Montreal, QC</i>	colorectal	Phase I
rNAPc2	Nuvelo <i>San Carlos, CA</i>	colorectal (see also heart disease)	Phase II (650) 517-8000
romidepsin	Gloucester Pharmaceuticals <i>Cambridge, MA</i>	prostate	Phase II (617) 583-1300
S-1	sanofi-aventis <i>Bridgewater, NJ</i> Taiho Pharma USA <i>Princeton, NJ</i>	colorectal	Phase III (800) 633-1610 (609) 750-5300

CANCER

Product Name	Company	Indication	Development Status
Sarasar™ lonafarnib	Schering-Plough <i>Kenilworth, NJ</i>	breast	Phase II (908) 298-4000
satraplatin	GPC Biotech <i>Waltham, MA</i> Spectrum Pharmaceuticals <i>Irvine, CA</i>	prostate	application submitted (781) 890-9007 (949) 788-6700
		breast, NSCLC	Phase II (781) 890-9007 (949) 788-6700
seocalcitol	Cougar Biotechnology <i>Los Angeles, CA</i>	prostate	Phase I (310) 943-8040
sibrotuzumab (BIBH 1)	Life Science Pharmaceuticals <i>Greenwich, CT</i>	colorectal, lung	Phase II (203) 422-6500
silibinin	Indena USA <i>Seattle, WA</i>	prostate	Phase I (206) 340-6140
SLIT™ cisplatin liposomal	Transave <i>Monmouth Junction, NJ</i>	lung	Phase II (732) 438-9434
SNS-595	Sunesis Pharmaceuticals <i>South San Francisco, CA</i>	NSCLC, SCLC	Phase II (650) 266-3500
Sprycel™ dasatinib	Bristol-Myers Squibb <i>Princeton, NJ</i>	breast, prostate	in clinical trials (212) 546-4000
Stimuvax® BLP25 liposomal vaccine	Biomira <i>Edmonton, AB</i>	NSCLC	Phase III (780) 450-3761
SU-14813	Pfizer <i>New York, NY</i>	breast	Phase II (860) 732-5156
Sutent® sunitinib maleate	Pfizer <i>New York, NY</i>	breast	Phase III (860) 732-5156
		colorectal, NSCLC, prostate	Phase II (860) 732-5156
tacedinaline	Pfizer <i>New York, NY</i>	breast, lung	Phase II (860) 732-5156
		colorectal	Phase I (860) 732-5156
talaporfin sodium	Light Sciences <i>Snoqualmine, WA</i>	colorectal	Phase II (425) 369-2760
TamoGel™ afimoxifene	ASCEND Therapeutics <i>Herndon, VA</i>	breast	Phase II (703) 471-4744
tanespimycin (KOS-953)	Abbott Laboratories <i>Abbott Park, IL</i>	breast	Phase II (847) 937-6100
Tarceva® erlotinib	Genentech <i>South San Francisco, CA</i> OSI Pharmaceuticals <i>Melville, NY</i>	breast	Phase II (650) 225-1000 (800) 572-1932

CANCER

Product Name	Company	Indication	Development Status
Targretin® Capsules bexarotene oral	Ligand Pharmaceuticals <i>San Diego, CA</i>	NSCLC	Phase III (858) 550-7500
		breast, colorectal, prostate	Phase II (858) 550-7500
tariquidar	QLT USA <i>Fort Collins, CO</i>	cervical, NSCLC	Phase II (800) 663-5486
TAS-108	Taiho Pharma USA <i>Princeton, NJ</i>	breast	Phase II (609) 750-5300
tasidotin	Genzyme Oncology <i>Cambridge, MA</i>	NSCLC, prostate	Phase II (617) 252-7500
T-cell gene therapy	Immunomedics <i>Morris Plains, NJ</i>	colorectal	Phase I (973) 605-8200
tegafur/uracil	Merck KGaA <i>Darmstadt, Germany</i>	colorectal	Phase III www.merck.de
temsirolimus	Wyeth Pharmaceuticals <i>Collegeville, PA</i>	colorectal, NSCLC, prostate	Phase II (800) 934-5556
terameprocol (EM-1421)	Erimos Pharmaceuticals <i>Raleigh, NC</i>	cervical intraepithelial neoplasia	Phase II (919) 821-5204
tesmilifene	YM Biosciences USA <i>Wayne, PA</i>	breast	Phase III (610) 560-0600
		prostate	Phase II (610) 560-0600
testosterone progressive hydration vaginal tablet	Columbia Laboratories <i>Livingston, NJ</i>	uterine leiomyoma	Phase I (866) 566-5636
tetrandrine	Millenia Hope <i>Montreal, QC</i>	colorectal	Phase III (514) 846-5757
Thalomid® thalidomide	Celgene <i>Summit, NJ</i>	colorectal, NSCLC (see also infectious diseases, lupus)	Phase III (908) 673-9000
		breast, prostate	Phase II (908) 673-9000
Thermodox™ heat-activated liposomal encapsulated doxorubicin	Celsion <i>Columbia, MD</i>	breast	Phase I (410) 290-5390
Thymitaq® nolatrexed	YM Biosciences USA <i>Wayne, PA</i>	colorectal, lung, prostate	Phase II (610) 560-0600
ticilimumab	Pfizer <i>New York, NY</i>	colorectal, NSCLC, prostate	Phase II (860) 732-5156

CANCER

Product Name	Company	Indication	Development Status
tigapotide	Ambrilia Biopharma <i>Verdun, QC</i>	prostate	Phase II (514) 751-2003
tirapazamine	SRI International <i>Menlo Park, CA</i>	cervical	Phase III (650) 859-2000
TNFerade™ tumour necrosis factor-alpha gene therapy	GenVec <i>Gaithersburg, MD</i>	colorectal	Phase II (877) 943-6832
Tocosol® paclitaxel	Sonus Pharmaceuticals <i>Bothell, WA</i> Bayer HealthCare Pharmaceuticals <i>Wayne, NJ</i>	breast colorectal, NSCLC	Phase III (425) 487-9500 (888) 84-BAYER Phase II (425) 487-9500 (888) 84-BAYER
TPI-287	Tapestry Pharmaceuticals <i>Boulder, CO</i>	prostate	Phase II (305) 516-8500
transgenic B lymphocyte immunotherapy (cancer vaccine)	Cosmo Pharmaceuticals <i>Lainate, Italy</i>	prostate	Phase II
trastuzumab-DM1	Genentech <i>South San Francisco, CA</i> ImmunoGen <i>Cambridge, MA</i>	breast	Phase I (650) 225-1000 (617) 995-2500
Trelstar® Depot triptorelin	Watson Pharmaceuticals <i>Corona, CA</i>	breast	Phase III (800) 249-5499
triacetyluridine	Wellstat Therapeutics <i>Gaithersburg, MD</i>	colorectal	Phase I (240) 631-2500
Triapine® OCX 0191	Vion Pharmaceuticals <i>New Haven, CT</i>	breast, NSCLC, prostate	Phase II (203) 498-4210
Trisenox™ arsenic trioxide	Cephalon <i>Frazer, PA</i>	breast, cervical, colorectal, NSCLC, prostate	Phase II (610) 344-0200
tucotuzumab celmoleukin	EMD Lexigen <i>Billerica, MA</i>	colorectal, NSCLC, ovarian, prostate	Phase II (978) 294-1100
Tykerb® lapatinib	GlaxoSmithKline <i>Philadelphia, PA</i> <i>Rsch. Triangle Park, NC</i>	refractory breast breast (adjuvant therapy), breast (first-line therapy)	application submitted (888) 825-5249 Phase III (888) 825-5249
UCN-01	Keryx Biopharmaceuticals <i>New York, NY</i>	SCLC	Phase II (212) 531-5965
ursodiol disulfate	Axcan Pharma <i>Mont-Saint-Hilaire, QC</i>	colorectal	Phase I (450) 467-5138

CANCER

Product Name	Company	Indication	Development Status
vatalanib	Novartis Pharmaceuticals <i>East Hanover, NJ</i>	colorectal	Phase III (888) NOW-NOVA
Vectibix™ panitumumab	Amgen <i>Thousand Oaks, CA</i>	NSCLC	Phase II (805) 447-1000
verpasep caltespen (HspE7) vaccine	Nventa Biopharmaceuticals <i>San Diego, CA</i> Roche <i>Nutley, NJ</i>	cervical, cervical dysplasia	Phase II (858) 202-4900 (973) 235-5000
vinflunine	Bristol-Myers Squibb <i>Princeton, NJ</i> Pierre Fabre Medicament <i>Paris, France</i>	breast, NSCLC	in clinical trials (212) 546-4000
vinorelbine	Novacea <i>South San Francisco, CA</i>	advanced breast (oral)	Phase III (650) 228-1800
		cervical (IV), prostate (oral), SCLC (IV)	Phase II (650) 228-1800
vorinostat (SAHA)	Aton Pharma <i>Lawrenceville, NJ</i>	colorectal	Phase I (877) ATON-549
VP101	Virium Pharmaceuticals <i>Princeton, NJ</i>	colorectal, prostate	Phase II (609) 951-2270
Xinlay™ atrasentan	Abbott Laboratories <i>Abbott Park, IL</i>	prostate	application submitted (847) 937-6100
		lung	Phase II (847) 937-6100
Xorane™ paclitaxel	IVAX <i>Miami, FL</i>	breast, NSCLC	Phase II (305) 575-6000
XRP6258 (taxoid tubulin inhibitor)	sanofi-aventis <i>Bridgewater, NJ</i>	prostate	Phase III (800) 633-1610
		breast tumors	Phase II (800) 633-1610
Yondelis® trabectedin	Johnson & Johnson Pharmaceutical Research & Development <i>Raritan, NJ</i>	breast, prostate	Phase II (800) 817-5286
Zactima® vandetanib	AstraZeneca <i>Wilmington, DE</i>	NSCLC	Phase III (800) 236-9933
		breast	Phase II (800) 236-9933
ZK epothilone	Bayer HealthCare Pharmaceuticals <i>Wayne, NJ</i>	breast, prostate	Phase II (888) 842-2937

DIABETES

Product Name	Company	Indication	Development Status
189075 (sodium-dependent glucose transport [SGLT2] antagonist)	GlaxoSmithKline Philadelphia, PA Rsch. Triangle Park, NC	type 2 diabetes (see also obesity)	Phase II (888) 825-5249
376501 (PPAR gamma partial agonist)	GlaxoSmithKline Philadelphia, PA Rsch. Triangle Park, NC	type 2 diabetes	Phase I (888) 825-5249
625019 (PPAR pan agonist)	GlaxoSmithKline Philadelphia, PA Rsch. Triangle Park, NC	type 2 diabetes	Phase I (888) 825-5249
677954 (PPAR pan agonist)	GlaxoSmithKline Philadelphia, PA Rsch. Triangle Park, NC	type 2 diabetes	Phase II (888) 825-5249
ABT-279	Abbott Laboratories Abbott Park, IL	type 2 diabetes	Phase I (847) 937-6100
Acomplia [®] rimonabant	sanofi-aventis Bridgewater, NJ	type 2 diabetes (see also obesity)	Phase III (800) 633-1610
AERx [®] iDMS insulin solution for inhalation (NN1998)	Aradigm Hayward, CA Novo Nordisk Princeton, NJ	type 1 diabetes, type 2 diabetes	Phase III (510) 265-9000 (800) 727-6500
AI-401	AutoImmune Pasadena, CA	type 1 diabetes prevention	Phase III (626) 792-1235
AKP-111	Akesis Pharmaceuticals San Diego, CA	type 2 diabetes	Phase I (858) 454-4311
AKP-320	Akesis Pharmaceuticals San Diego, CA	type 2 diabetes	in clinical trials (858) 454-4311
albiglutide (716155)	GlaxoSmithKline Philadelphia, PA Rsch. Triangle Park, NC	type 2 diabetes	Phase II (888) 825-5249
Albulin [™] albumin/insulin	CoGenesys Rockville, MD	type 1 diabetes, type 2 diabetes	in clinical trials (240) 821-9000
aleglitazar (R1439)	Roche Nutley, NJ	type 2 diabetes	Phase II (973) 235-5000
alogliptin	Takeda Pharmaceuticals North America Deerfield, IL	diabetes	Phase III (224) 554-6500
ALS-20426	Alantos Pharmaceuticals Cambridge, MA	type 2 diabetes	Phase I (617) 577-0011
Altace [®] ramipril	King Pharmaceuticals Bristol, TN	type 2 diabetes prevention (see also kidney diseases)	Phase III (800) 776-3637
Alveair [™] inhaled insulin	Coremed Lake Bluff, IL	diabetes	Phase I (847) 549-9098
AMG 221	Amgen Thousand Oaks, CA	type 2 diabetes	Phase I (800) 77-AMGEN

DIABETES

Product Name	Company	Indication	Development Status
APD-668	Arena Pharmaceuticals <i>San Diego, CA</i> Johnson & Johnson Pharmaceutical Research & Development <i>Raritan, NJ</i>	type 2 diabetes	Phase I (858) 453-7200 (800) 817-5286
Apidra® SoloStar® insulin glulisine	sanofi-aventis <i>Bridgewater, NJ</i>	type 2 diabetes	application submitted (800) 633-1610
AT-1391 (daily insulin skin patch)	Altea Therapeutics <i>Tucker, GA</i>	type 1 diabetes, type 2 diabetes	Phase I (678) 495-3100
Avandia® rosiglitazone	GlaxoSmithKline <i>Philadelphia, PA</i> <i>Rsch. Triangle Park, NC</i>	type 2 diabetes prevention, prevention of disease progression	Phase III (888) 825-5249
Avandia® rosiglitazone/ simvastatin combination	GlaxoSmithKline <i>Philadelphia, PA</i> <i>Rsch. Triangle Park, NC</i>	type 1 diabetes	Phase I (888) 825-5249
AVE0010 (GLP1 agonist)	sanofi-aventis <i>Bridgewater, NJ</i>	type 2 diabetes	Phase II (800) 633-1610
AVE0847 (PPAR-alpha agonist with additional gamma agonist)	sanofi-aventis <i>Bridgewater, NJ</i>	type 2 diabetes	Phase II (800) 633-1610
AVE0897 (balanced PPAR-alpha and gamma agonist)	sanofi-aventis <i>Bridgewater, NJ</i>	type 2 diabetes	Phase I (800) 633-1610
AVE2268 (SGLT-2 inhibitor)	sanofi-aventis <i>Bridgewater, NJ</i>	type 2 diabetes	Phase II (800) 633-1610
AVE8134 (PPAR-alpha agonist)	sanofi-aventis <i>Bridgewater, NJ</i>	type 2 diabetes (see also heart disease)	Phase II (800) 633-1610
AVR118	Advanced Viral Research <i>Yonkers, NY</i>	type 2 diabetes	Phase I (914) 376-7383
BHT-3021	Bayhill Therapeutics <i>Palo Alto, CA</i>	type 1 diabetes	Phase I (650) 320-2800
BI-1356 BS	Boehringer Ingelheim Pharmaceuticals <i>Ridgefield, CT</i>	type 2 diabetes	Phase II (800) 243-0127
bromocriptine	VeroScience <i>Tiverton, RI</i> Wythe Therapeutics <i>Bristol, TN</i>	type 2 diabetes	Phase III (401) 816-0525

DIABETES

Product Name	Company	Indication	Development Status
cetilistat	Alizyme <i>Cambridge, UK</i>	type 2 diabetes (see also obesity)	Phase II www.alizyme.com
CRx-401	CombinatoRx <i>Cambridge, MA</i>	type 2 diabetes	Phase I (617) 301-7000
CS-917	Daiichi Sankyo <i>Parsippany, NJ</i> Metabasis Therapeutics <i>San Diego, CA</i>	type 2 diabetes	Phase II (973) 359-2600 (858) 587-2770
dapagliflozin (SGLT2 inhibitor)	AstraZeneca <i>Wilmington, DE</i> Bristol-Myers Squibb <i>Princeton, NJ</i>	diabetes	Phase II (800) 236-9933 (212) 546-4000
DiaPep 277®	Andromeda Biotech <i>Tel-Aviv, Israel</i>	latent autoimmune diabetes in adults	Phase II
DIO-902	DiObex <i>San Francisco, CA</i>	type 2 diabetes	Phase II (415) 551-0400
epidermal growth factor	Novo Nordisk <i>Princeton, NJ</i> Transition Therapeutics <i>Toronto, ON</i>	type 1 diabetes, type 2 diabetes	Phase II (800) 727-6500 (416) 260-7770
exenatide intranasal	Amylin Pharmaceuticals <i>San Diego, CA</i> Nastech Pharmaceutical <i>Bothell, WA</i>	type 2 diabetes	Phase I (858) 552-2200 (425) 908-3600
exenatide LAR (long-acting release)	Alkermes <i>Cambridge, MA</i> Amylin Pharmaceuticals <i>San Diego, CA</i> Eli Lilly <i>Indianapolis, IN</i>	type 2 diabetes	Phase II (617) 494-0171 (858) 552-2200 (800) 545-5979
Galvus® vildagliptin	Novartis Pharmaceuticals <i>East Hanover, NJ</i>	type 2 diabetes	application submitted (888) NOW-NOVA
GLP-1 agonist	Bristol-Myers Squibb <i>Princeton, NJ</i>	diabetes	Phase I (212) 546-4000
GLP-1 analogue	Eli Lilly <i>Indianapolis, IN</i>	type 2 diabetes	Phase I (800) 545-5979
INCB-13739	Incyte <i>Wilmington, DE</i>	type 2 diabetes	Phase II (302) 498-6944
INGAP peptide	Procter & Gamble Pharmaceuticals <i>Cincinnati, OH</i>	type 1 diabetes, type 2 diabetes	Phase I
inhalation insulin	Innovata <i>Nottingham, UK</i> MicroDose Technologies <i>Monmouth Junction, NJ</i>	diabetes	Phase I (212) 546-4000

DIABETES

Product Name	Company	Indication	Development Status
insulin inhalation	Alkermes <i>Cambridge, MA</i> Eli Lilly <i>Indianapolis, IN</i>	diabetes	Phase III (617) 494-0171 (800) 545-5979
insulin inhalation (KI 02212)	Abbott Laboratories <i>Abbott Park, IL</i>	diabetes	Phase II (847) 937-6100
insulin intranasal	Nastech Pharmaceutical <i>Bothell, WA</i>	diabetes	Phase I (425) 908-3600
insulin transdermal	Dermisonics <i>Irvine, CA</i>	type 1 diabetes, type 2 diabetes	Phase I (888) 401-3376
INT-131	InteKrin Therapeutics <i>Los Altos, CA</i>	type 2 diabetes	Phase II (650) 941-5501
Intensulin™ insulin oral	Coremed <i>Lake Bluff, IL</i>	diabetes	Phase I (847) 772-6868
ISIS 113715	Isis Pharmaceuticals <i>Carlsbad, CA</i>	type 2 diabetes	Phase II (760) 931-9200
K-111	Kowa Pharmaceuticals <i>Morrisville, NC</i>	type 2 diabetes	Phase II (919) 433-1600
KRP-104	ActivX Biosciences <i>La Jolla, CA</i>	type 2 diabetes	Phase I (858) 558-5558
liraglutide (NN2211)	Novo Nordisk <i>Princeton, NJ</i>	type 2 diabetes	Phase III (800) 727-6500
MB-07803	Metabasis Therapeutics <i>San Diego, CA</i>	type 2 diabetes	Phase II (858) 587-2770
MBX-2044	Johnson & Johnson Pharmaceutical Research & Development <i>Raritan, NJ</i> Metabolex <i>Hayward, CA</i>	type 2 diabetes	Phase II (800) 817-5286 (510) 293-8800
metaglidase (MBX-102)	Johnson & Johnson Pharmaceutical Research & Development <i>Raritan, NJ</i> Metabolex <i>Hayward, CA</i>	type 2 diabetes	Phase II (800) 817-5286 (510) 293-8800
metformin buccal (chewing gum)	Genexx Biotechnology <i>Toronto, ON</i>	type 2 diabetes	in clinical trials (416) 364-2551
mitiglinide	Elixir Pharmaceuticals <i>Cambridge, MA</i>	type 2 diabetes	Phase II (617) 995-7000
MK-0533	Merck <i>Whitehouse Station, NJ</i>	diabetes	Phase II (800) 672-6372
MK-0893	Merck <i>Whitehouse Station, NJ</i>	diabetes	Phase I (800) 672-6372

DIABETES

Product Name	Company	Indication	Development Status
MK-0941	Merck <i>Whitehouse Station, NJ</i>	diabetes	Phase I (800) 672-6372
MK-1642	Merck <i>Whitehouse Station, NJ</i>	type 2 diabetes	Phase I (800) 672-6372
MK-3887	Merck <i>Whitehouse Station, NJ</i>	diabetes	Phase I (800) 672-6372
Nasulin™ insulin intranasal	Bentley Pharmaceuticals <i>Exeter, NH</i>	type 1 diabetes	Phase II (603) 658-6100
Naturlose® tagatose	Spherix <i>Beltsville, MD</i>	type 2 diabetes	Phase III (301) 419-3900
naveglitazar (PPAR modulator)	Eli Lilly <i>Indianapolis, IN</i> Ligand Pharmaceuticals <i>San Diego, CA</i>	type 2 diabetes	Phase II (800) 545-5979 (858) 550-7500
NBI-6024	Neurocrine Biosciences <i>San Diego, CA</i>	type 1 diabetes	Phase II (858) 617-7600
ONO-5129	Ono Pharma USA <i>New Jersey, NJ</i>	type 2 diabetes	Phase II
oral insulin	Emisphere Technologies <i>Tarrytown, NY</i>	type 2 diabetes	Phase II (914) 347-2220
PEG-encapsulated islet cell transplantation therapy	Novocell <i>San Diego, CA</i>	type 1 diabetes	Phase I (858) 455-3708
PF-734200	Pfizer <i>New York, NY</i>	type 2 diabetes	Phase II (860) 732-5156
PF-915275	Pfizer <i>New York, NY</i>	type 2 diabetes	Phase I (860) 732-5156
PHX-1149	Phenomix <i>San Diego, CA</i>	type 2 diabetes	Phase II (858) 731-5200
pioglitazone/ metformin extended release	Takeda Pharmaceuticals North America <i>Deerfield, IL</i>	type 2 diabetes	application submitted (224) 554-6500
PPM-201	Wyeth Pharmaceuticals <i>Collegeville, PA</i>	type 2 diabetes	Phase I (800) 934-5556
PPM-202	Wyeth Pharmaceuticals <i>Collegeville, PA</i>	type 2 diabetes	Phase I (800) 934-5556
PPM-204	Plexxikon <i>Berkeley, CA</i> Wyeth Pharmaceuticals <i>Collegeville, PA</i>	type 2 diabetes	Phase II (510) 647-4000 (800) 934-5556
Promaxx™ recombinant human insulin inhalation powder	Baxter Healthcare <i>Deerfield, IL</i>	diabetes	Phase I (800) 4-BAXTER

DIABETES

Product Name	Company	Indication	Development Status
pyrazinoyl-guanidine	SuperGen <i>Dublin, CA</i>	type 2 diabetes	Phase II (925) 560-0100
rivoglitazone	Daiichi Sankyo <i>Parsippany, NJ</i>	type 2 diabetes	Phase II (973) 359-2600
RO 0730699	Roche <i>Nutley, NJ</i>	type 2 diabetes	Phase II (973) 235-5000
RO 4389620	Roche <i>Nutley, NJ</i>	type 2 diabetes	Phase II (973) 235-5000
saxagliptin (DPP4 inhibitor)	AstraZeneca <i>Wilmington, DE</i> Bristol-Myers Squibb <i>Princeton, NJ</i>	diabetes	Phase III (800) 236-9933 (212) 546-4000
SRT-501	Sirtris Pharmaceuticals <i>Cambridge, MA</i>	type 2 diabetes	Phase I (617) 252-6920
TA-6666	Tanabe Seiyaku <i>Osaka, Japan</i>	type 2 diabetes	Phase II
Technosphere® Insulin insulin inhalation	MannKind <i>Valencia, CA</i>	type 1 diabetes, type 2 diabetes	Phase III (661) 725-5300
teplizumab	MacroGenics <i>Rockville, MD</i>	type 1 diabetes	Phase II (301) 251-5172
TPP-355	TransTech Pharma <i>High Point, NC</i>	diabetes	Phase I (336) 841-0300
TRX4 (anti-CD3 MAb)	TolerRx <i>Cambridge, MA</i>	type 1 diabetes	Phase I (617) 354-8100
TS-021	Taisho Pharmaceutical R&D <i>Morristown, NJ</i>	type 2 diabetes	Phase I
WelChol® colesevelam	Daiichi Sankyo <i>Parsippany, NJ</i>	type 2 diabetes	application submitted (973) 359-2600

GLAUCOMA

Product Name	Company	Indication	Development Status
C-3859	Merck <i>Whitehouse Station, NJ</i>	glaucoma	Phase I (800) 672-6372
C-9993	Merck <i>Whitehouse Station, NJ</i>	glaucoma	Phase I (800) 672-6372
Combigan™ brimonidine/ timolol combination	Allergan <i>Irvine, CA</i>	glaucoma	application submitted (714) 246-4500

GLAUCOMA

Product Name	Company	Indication	Development Status
DuoTrav™ travoprost/timolol combination	Alcon Research <i>Fort Worth, TX</i>	glaucoma	application submitted (800) 862-5266
Ganfort® bimatoprost/ timolol combination	Allergan <i>Irvine, CA</i>	glaucoma	application submitted (714) 246-4500
INS115644	Inspire Pharmaceuticals <i>Durham, NC</i>	glaucoma	Phase I (919) 941-9777
memantine	Allergan <i>Irvine, CA</i>	glaucoma	Phase III (714) 246-4500
PF-03187207	Pfizer <i>New York, NY</i>	glaucoma	Phase II (860) 732-5156
Retaane® anecortave acetate	Alcon Research <i>Fort Worth, TX</i>	glaucoma	Phase II (800) 862-5266
tafluprost (DE-085)	Santen Pharmaceutical <i>Napa, CA</i>	glaucoma	Phase III (707) 254-1750

HEART DISEASE

Product Name	Company	Indication	Development Status
ABI-007	Abraxis BioScience <i>Los Angeles, CA</i> AstraZeneca <i>Wilmington, DE</i>	coronary artery restenosis (see also cancer)	Phase II (310) 437-7700 (800) 236-9933
Adentri™	Biogen Idec <i>Cambridge, MA</i> CV Therapeutics <i>Palo Alto, CA</i>	congestive heart failure	Phase II (650) 384-8500
alagebrium (ALT-711)	Alteon <i>Montvale, NJ</i>	heart failure, hypertension (see also kidney diseases)	Phase II (201) 934-5000
aliskiren/hydro- chlorothiazide fixed-dose combination	Novartis Pharmaceuticals <i>East Hanover, NJ</i>	hypertension	application submitted (888) NOW-NOVA
Altace HCT® ramipril/hydro- chlorothiazide	King Pharmaceuticals <i>Bristol, TN</i>	hypertension	Phase III (800) 776-3637
AMR 001	Amorcyte <i>Hackensack, NJ</i>	myocardial infarction	Phase I
Angiomax® bivalirudin	The Medicines Company <i>Parsippany, NJ</i>	acute coronary syndrome	Phase III (973) 656-1616
apadenoson	Adenosine Therapeutics <i>Charlottesville, VA</i>	coronary artery restenosis (see also infectious diseases)	Phase I (434) 220-9400

HEART DISEASE

Product Name	Company	Indication	Development Status
apixaban (factor Xa inhibitor)	Bristol-Myers Squibb <i>Princeton, NJ</i> Pfizer <i>New York, NY</i>	secondary prevention of acute coronary syndrome (see also stroke)	in clinical trials (212) 546-4000 (860) 732-5156
Aranesp [®] darbepoetin alfa	Amgen <i>Thousand Oaks, CA</i>	heart failure	Phase III (805) 447-1000
argatroban	Encysive Pharmaceuticals <i>Houston, TX</i>	myocardial infarction (see also stroke)	Phase II (713) 796-8822
Arixtra [®] fondaparinux	GlaxoSmithKline <i>Philadelphia, PA</i> <i>Rsch. Triangle Park, NC</i>	acute coronary syndrome	application submitted (888) 825-5249
ataciguat (HMR1766)	sanofi-aventis <i>Bridgewater, NJ</i>	pulmonary arterial hypertension	Phase II (800) 633-1610
autologous stem cell therapy	Aldagen <i>Durham, NC</i>	heart failure	Phase I (919) 484-2571
Avapro [®] irbesartan	sanofi-aventis <i>Bridgewater, NJ</i> Bristol-Myers Squibb <i>Princeton, NJ</i>	heart failure with preserved systolic function	Phase III (800) 633-1610 (212) 546-5000
AVE3085 (e-NOS transcription enhancer)	sanofi-aventis <i>Bridgewater, NJ</i>	congestive heart failure	Phase I (800) 633-1610
AVE8134 (PPAR-alpha agonist)	sanofi-aventis <i>Bridgewater, NJ</i>	congestive heart failure (see also diabetes)	Phase II (800) 633-1610
AVI-4126	AVI BioPharma <i>Portland, OR</i>	coronary artery restenosis	Phase I/II (503) 227-0554
AZD-6140	AstraZeneca <i>Wilmington, DE</i>	acute coronary syndrome	Phase III (800) 236-9933
azilsartan	Takeda Pharmaceuticals North America <i>Deerfield, IL</i>	hypertension	Phase II (224) 554-6500
azimilide	Procter & Gamble Pharmaceuticals <i>Cincinnati, OH</i>	post-myocardial infarction	Phase III
beraprost sustained-release	United Therapeutics <i>Silver Spring, MD</i>	pulmonary hypertension	Phase I (301) 608-9292
Bidil XR [™] hydralazine hydrochloride/ isosorbide dinitrate	NitroMed <i>Lexington, MA</i>	heart failure	Phase I (781) 266-4000
biolimus A9	Devax <i>Irvine, CA</i>	coronary artery restenosis	Phase I (949) 461-0450

HEART DISEASE

Product Name	Company	Indication	Development Status
bucindolol	Indevus Pharmaceuticals <i>Lexington, MA</i>	heart failure	Phase III (781) 861-8444
Caldaret (MCC-135)	Mitsubishi Pharma America <i>Warren, NJ</i>	myocardial infarction	Phase II (908) 607-1950
Cardeva™ B-type natriuretic peptide	CoGenesys <i>Rockville, MD</i>	chronic heart failure	Phase I (240) 821-9000
carperitide	Asubio Pharmaceuticals <i>Rochelle Park, NJ</i>	heart failure	Phase II (201) 368-5020
Celacade™ immune modulation therapy	Vasogen <i>Mississauga, Ontario</i>	congestive heart failure	Phase III (905) 817-2000
Certican® everolimus	Abbott Laboratories <i>Abbott Park, IL</i>	coronary artery restenosis	application submitted (847) 936-1189
CK-1827452	Cytokinetics <i>South San Francisco, CA</i>	heart failure	Phase I (650) 624-3000
Cleavelox™ clevidipine	The Medicines Company <i>Parsippany, NJ</i>	perioperative hypertension	Phase III (800) 388-1183
Corlopam® intravenous fenoldopam	Elan Pharmaceuticals <i>New York, NY</i>	congestive heart failure (see also kidney diseases)	Phase II (212) 407-5740
coronary artery disease gene therapy	BioCardia <i>South San Francisco, CA</i>	coronary artery disease	Phase II (650) 624-0900
CYT 006	Cytos Biotechnology <i>Zurich, Switzerland</i>	hypertension	Phase II www.cytos.com
daglutril	Solvay Pharmaceuticals <i>Marietta, GA</i>	congestive heart failure, hypertension	Phase II (770) 578-9000
darusentan	Gilead Sciences <i>Foster City, CA</i>	resistant hypertension	Phase III (800) GILEAD-5
diltiazem	DOV Pharmaceutical <i>Somerset, NJ</i>	hypertension	Phase I (732) 907-3600
doxycycline hyclate	CollaGenex Pharmaceuticals <i>Newton, PA</i>	acute coronary syndrome	in clinical trials (215) 579-7388
DX9065a	Daiichi Sankyo <i>Parsippany, NJ</i>	acute coronary syndrome, coronary artery restenosis	Phase II (973) 359-2600
E5555	Eisai <i>Ridgefield Park, NJ</i>	acute coronary syndrome (critical care)	Phase I (201) 403-2500
ecadotril	Bayer HealthCare Pharmaceuticals <i>Wayne, NJ</i>	heart failure	Phase II (888) 84-BAYER

HEART DISEASE

Product Name	Company	Indication	Development Status
Endeavor™ zotarolimus	Medtronic <i>Minneapolis, MN</i>	coronary artery restenosis	application submitted (763) 514-4000
estradiol/ drospirenone	Bayer HealthCare Pharmaceuticals <i>Wayne, NJ</i>	hypertension	Phase III (888) 84-BAYER
ETC-216	Pfizer <i>New York, NY</i>	acute coronary syndrome, coronary artery disease	Phase II (860) 732-5156
fluvastatin	Novartis Pharmaceuticals <i>East Hanover, NJ</i>	coronary artery restenosis	in clinical trials (888) NOW-NOVA
furosemide GR	Depomed <i>Menlo Park, CA</i>	congestive heart failure	Phase II (650) 462-5900
glucagon-like peptide-1	Amylin Pharmaceuticals <i>San Diego, CA</i>	congestive heart failure	Phase II (858) 552-2200
HMR1069	sanofi-aventis <i>Bridgewater, NJ</i>	pulmonary arterial hypertension	Phase I (800) 633-1610
hydralazine (BPI-103)	PDL BioPharma <i>Fremont, CA</i>	hypertension in pregnancy	in clinical trials (510) 574-1400
icodextrin solution	Baxter Healthcare <i>Deerfield, IL</i>	congestive heart failure	Phase II (800) 4BAXTER
ilepatril (ACE/NEP inhibitor)	sanofi-aventis <i>Bridgewater, NJ</i>	hypertension (see also kidney diseases)	Phase II (800) 633-1610
imidapril	Xanodyne Pharmaceuticals <i>Newport, KY</i>	hypertension	Phase II (877) XANODYNE
Integrilin® eptifibatide	Schering-Plough <i>Kenilworth, NJ</i>	early acute coronary syndrome	Phase III (908) 298-4000
J-104132	Merck <i>Whitehouse Station, NJ</i>	congestive heart failure, hypertension	Phase II (800) 672-6372
KAI-9803	KAI Pharmaceuticals <i>South San Francisco, CA</i>	prevention of reperfusion injury following acute myocardial infarction	Phase I/II (650) 244-1100
Kuvan™ sapropterin	BioMarin Pharmaceutical <i>Novato, CA</i> EMD Serono <i>Rockford, MA</i>	hypertension (see also sickle cell disease)	Phase II (415) 506-6700 (800) 283-8088
KW-3902	NovaCardia <i>San Diego, CA</i>	heart failure (IV)	Phase III (858) 509-0455
		heart failure (PO)	Phase I (858) 509-0455
Lantus® insulin glargine	sanofi-aventis <i>Bridgewater, NJ</i>	reduction in cardiovascular morbidity and mortality associated with diabetes	Phase III (800) 633-1610
LCI-699	Novartis Pharmaceuticals <i>East Hanover, NJ</i>	hypertension	Phase I (888) NOW-NOVA

HEART DISEASE

Product Name	Company	Indication	Development Status
M 118	Momenta Pharmaceuticals <i>Cambridge, MA</i>	acute coronary syndrome	Phase I (617) 491-9700
MC-1	Medicure <i>Winnipeg, Canada</i>	myocardial infarction (see also stroke)	Phase III (888) 435-2220
mesenchymal stem cell therapy	Boston Scientific <i>Natick, MA</i> Osiris Therapeutics <i>Baltimore, MD</i>	acute myocardial infarction	Phase I (410) 522-5005
MK-0736	Merck <i>Whitehouse Station, NJ</i>	hypertension	Phase II (800) 672-6372
moxonidine	Solvay Pharmaceuticals <i>Marietta, GA</i>	hypertension	Phase III (770) 578-9000
mycophenolic acid	Avantec Vascular <i>Sunnyvale, CA</i>	coronary artery restenosis	in clinical trials (408) 329-5400
myoblast cell transplantation therapy	Mytogen <i>Charlestown, MA</i>	congestive heart failure	Phase I (617) 242-9100
MyoCell™ cell-based heart damage therapy	Bioheart <i>Sunrise, FL</i>	congestive heart failure	Phase I (954) 835-1500
Natrecor® nesiritide	Scios <i>Mountain View, CA</i>	chronic heart failure (IV-infusion)	Phase II (650) 564-5000
		heart failure (subcutaneous)	Phase I (650) 564-5000
nebivolol	Forest Laboratories <i>New York, NY</i> Mylan Laboratories <i>Canonsburg, PA</i>	hypertension	application submitted (724) 514-1800 (800) 947-5227
NEU-2000	Amkor Pharma <i>Seattle, WA</i>	myocardial infarction (see also stroke)	Phase I (206) 332-5587
olmesartan medoxomil/ amlodipine	Daiichi Sankyo <i>Parsippany, NJ</i>	hypertension	application submitted (973) 359-2600
otamixaban (XRP0673)	sanofi-aventis <i>Bridgewater, NJ</i>	acute coronary syndrome	Phase II (800) 633-1610
PF-489791	Pfizer <i>New York, NY</i>	hypertension	Phase I (860) 732-5156
PG 116800	Procter & Gamble Pharmaceuticals <i>Cincinnati, OH</i>	heart failure	Phase II
prasugrel (CS-747)	Eli Lilly <i>Indianapolis, IN</i> Daiichi Sankyo <i>Parsippany, NJ</i>	acute coronary syndrome	Phase III (800) 545-5979 (973) 359-2600

HEART DISEASE

Product Name	Company	Indication	Development Status
PRT-060128 (ADP receptor inhibitor)	Portola Pharmaceuticals <i>South San Francisco, CA</i>	acute coronary syndrome	Phase I (650) 246-7000
PRX-08066	EPIX Pharmaceuticals <i>Lexington, MA</i>	pulmonary hypertension	Phase II (781) 761-7600
PS-433540	Pharmacopeia Drug Discovery <i>Cranbury, NJ</i>	hypertension (see also kidney diseases)	Phase I (609) 452-3600
PulmoLAR™ 2-methoxyestradiol	PR Pharmaceuticals <i>Fort Collins, CO</i>	pulmonary hypertension	Phase I (970) 484-5560
Ranexa™ ranolazine	CV Therapeutics <i>Palo Alto, CA</i>	acute coronary syndrome	Phase III (650) 384-8500
Refludan® lepirudin	Bayer HealthCare Pharmaceuticals <i>Wayne, NJ</i>	myocardial infarction	application submitted (888) 84-BAYER
Remodulin® treprostinil (inhalation)	United Therapeutics <i>Silver Spring, MD</i>	pulmonary hypertension	Phase II (301) 608-9292
		congestive heart failure	Phase I (301) 608-9292
Rendix™ dabigatran etexilate	Boehringer Ingelheim Pharmaceuticals <i>Ridgefield, CT</i>	myocardial infarction	Phase I (203) 798-9988
ReoPro® abciximab	Centocor <i>Horsham, PA</i> Eli Lilly <i>Indianapolis, IN</i>	myocardial infarction	Phase III (610) 651-6000
Revlimid™ lenalidomide	Celgene <i>Summit, NJ</i>	congestive heart failure	Phase II (908) 673-9000
rivaroxaban	Bayer HealthCare Pharmaceuticals <i>Wayne, NJ</i> Ortho-McNeil <i>Raritan, NJ</i>	acute coronary syndrome (see also stroke)	Phase II (888) 84-BAYER (800) 817-5286
rNAPc2	Nuvelo <i>San Carlos, CA</i>	acute coronary syndrome (see also cancer)	Phase II (650) 517-8000
SCH 530348	Schering-Plough <i>Kenilworth, NJ</i>	acute coronary syndrome	Phase III (908) 298-4000
sitaxsentan	Encysive Pharmaceuticals <i>Houston, TX</i>	pulmonary hypertension	application submitted (713) 796-8822
		coronary disorders	Phase I (713) 796-8822
SLV 320	Solvay Pharmaceuticals <i>Marietta, GA</i>	congestive heart failure (see also kidney diseases)	Phase II (770) 578-9000

HEART DISEASE

Product Name	Company	Indication	Development Status
SLx-2101	Surface Logix <i>Brighton, MA</i>	hypertension	Phase II (617) 746-8500
		cardiovascular disorders	Phase I (617) 746-8500
SPP-1148	Speedel Pharmaceuticals <i>Bridgewater, NJ</i>	hypertension	Phase I (732) 537-2290
SR 123781	sanofi-aventis <i>Bridgewater, NJ</i>	prevention of major cardiovascular events in acute coronary syndrome	Phase II (800) 633-1610
tadalafil	Eli Lilly <i>Indianapolis, IN</i>	pulmonary hypertension	Phase III (317) 276-2000
		hypertension	Phase II (317) 276-2000
TAK-491	Takeda Pharmaceuticals North America <i>Deerfield, IL</i>	hypertension	Phase II (224) 554-6500
TB4	RegenRx Pharmaceuticals <i>Bethesda, MD</i>	post-myocardial infarction	Phase I (301) 280-1992
TBC3711	Encysive Pharmaceuticals <i>Houston, TX</i>	resistant hypertension	Phase II (713) 796-8822
		cardiovascular disorders, heart failure, pulmonary hypertension	Phase I (713) 796-8822
TG100-115	TargeGen <i>San Diego, CA</i>	myocardial infarction	Phase II (858) 678-0760
Thelin [®] sitaxsentan	Encysive Pharmaceuticals <i>Houston, TX</i>	pulmonary hypertension	application submitted (713) 796-8822
		coronary disorders	Phase I (713) 796-8822
Tikosyn [®] dofetilide	Pfizer <i>New York, NY</i>	post-myocardial infarction	Phase III (860) 732-5156
tolvaptan (OPC-41061)	Otsuka America Pharmaceutical <i>Rockville, MD</i>	congestive heart failure (see also kidney diseases)	Phase III (800) 562-3974
toremide ER	Penwest Pharmaceuticals <i>Danbury, CT</i>	edema in heart failure	Phase II (203) 796-3700
trimazosin	Pfizer <i>New York, NY</i>	hypertension	application submitted (860) 732-5156
UK-369003	Pfizer <i>New York, NY</i>	pulmonary hypertension	Phase II (860) 732-5156
urocortin 2	Neurocrine Biosciences <i>San Diego, CA</i>	congestive heart failure	Phase II (858) 617-7600
V10153	Vernalis Pharmaceuticals <i>Morristown, NJ</i>	myocardial infarction (see also stroke)	Phase II (973) 867-5555

HEART DISEASE

Product Name	Company	Indication	Development Status
valsartan	Novartis Pharmaceuticals <i>East Hanover, NJ</i>	hypertension	Phase III (888) NOW-NOVA
Veletri™ tezosentan	Actelion Pharmaceuticals USA <i>South San Francisco, CA</i>	heart failure	Phase III (650) 624-6900
VMD 30283	VM Discovery <i>Fremont, CA</i>	myocardial infarction	Phase I (510) 661-6770
VNP-489	Novartis Pharmaceuticals <i>East Hanover, NJ</i>	hypertension	Phase I (888) NOW-NOVA
VT-111	Viron Therapeutics <i>London, Ontario</i>	acute coronary syndrome	Phase II (519) 858-5109
		coronary artery restinosis	Phase I (519) 858-5109
Vytorin™ ezetimibe/ simvastatin	Merck <i>Whitehouse Station, NJ</i> Schering-Plough <i>Kenilworth, NJ</i>	acute coronary syndrome	Phase III (800) 672-6372 (908) 298-4000
ZP120	Zealand Pharma <i>Glostrup, Denmark</i>	congestive heart failure	Phase II www.zp.dk

INFECTIOUS DISEASES

Product Name	Company	Indication	Development Status
364735 (integrase inhibitor)	GlaxoSmithKline <i>Philadelphia, PA</i> <i>Rsch. Triangle Park, NC</i> Shionogi USA <i>Florham Park, NJ</i>	HIV infection treatment	Phase II (888) 825-5249 (973) 966-6900
ADVAX	Aaron Diamond AIDS Research Center <i>New York, NY</i> International AIDS Vaccine Initiative <i>New York, NY</i>	HIV infection prevention	Phase I (212) 448-5000 (212) 847-1111
AERAS-402	Aeras Global TB Vaccine Foundation <i>Rockville, MD</i>	tuberculosis	Phase I (301) 547-2900
AG-1859	Pfizer <i>New York, NY</i>	HIV infection treatment	Phase II (860) 732-5156
Alferon LDO®	Hemispherx Biopharma <i>Philadelphia, PA</i>	HIV infection treatment	Phase II (215) 988-0080
AMD070	Genzyme <i>Cambridge, MA</i>	HIV-1 infection	Phase I (617) 252-7500
amdoxovir	RFS Pharma <i>Tucker, GA</i>	HIV infection treatment	Phase II (404) 601-1430

INFECTIOUS DISEASES

Product Name	Company	Indication	Development Status
Ampligen®	Hemispherx Biopharma <i>Philadelphia, PA</i>	HIV infection treatment	Phase II (215) 988-0080
AMZ-0026	Amazon Biotech <i>New York, NY</i>	HIV infection treatment	Phase II (212) 947-3362
anti-CCR5 MAb	Human Genome Sciences <i>Rockville, MD</i>	HIV infection treatment	Phase I (301) 309-5804
anti-CD8 MAb	CytoDyn <i>Santa Fe, NM</i>	HIV infection treatment	Phase II (505) 988-5520
anti-HIV-1 human MAb 2G12, 2F5, 4E10	Polymun Scientific <i>Vienna, Austria</i>	HIV infection treatment	Phase II
antineoplaston AS2 1 (oral)	Burzynski Research Institute <i>Houston, TX</i>	HIV infection treatment (see also cancer)	Phase II (713) 335-5697
apadenoson	Adenosine Therapeutics <i>Charlottesville, VA</i>	septic shock (see also heart disease)	Phase I (434) 220-9400
apricitabine (AVX754)	Avexa <i>Richmond, Australia</i>	HIV-1 infection	Phase I www.avexa.com
AVX-101	AlphaVax <i>Rsch. Triangle Park, NC</i>	HIV-1 infection	Phase I (919) 595-0400
BAY 50-4798	Bayer HealthCare Pharmaceuticals <i>Wayne, NJ</i>	HIV infection treatment	Phase I (888) 84-BAYER
bevirimat (PA-457)	Panacos Pharmaceuticals <i>Watertown, MA</i>	HIV infection treatment	Phase II (617) 926-1551
calanolide A	Sarawack MediChem Pharmaceuticals <i>Woodridge, IL</i>	HIV-1 infection, tuberculosis	Phase I (630) 739-6744
CYT-107	Cytheris <i>Rockville, MD</i>	HIV infection	Phase I www.cytheris.com
CytoFab™ anti-TNFalpha polyclonal antibody	AstraZeneca <i>Wilmington, DE</i>	septic shock	Phase II (800) 236-9933
dapivirine	International Partnership for Microbicides <i>Silver Spring, MD</i>	HIV infection prevention	Phase I (301) 608-2221
DP-6001 (HIV DNA vaccine)	CytRx <i>Los Angeles, CA</i>	HIV infection prevention	Phase I (310) 826-5648
elvitegravir	Gilead Sciences <i>Foster City, CA</i>	HIV infection treatment	Phase II (800) GILEAD-5
elvucitabine	Achillion Pharmaceuticals <i>New Haven, CT</i>	HIV infection treatment	Phase II (203) 624-7000

INFECTIOUS DISEASES

Product Name	Company	Indication	Development Status
Emtriva® emtricitabine	Gilead Sciences <i>Foster City, CA</i>	hepatitis B	Phase III (800) GILEAD-5
Enbrel® etanercept	Amgen <i>Thousand Oaks, CA</i> Wyeth Pharmaceuticals <i>Collegeville, PA</i>	HIV-1 infection	Phase I
EP-1043	Pharmexa-Epimmune <i>San Diego, CA</i>	HIV-1 infection	Phase I (858) 860-2500
EP-1090	Pharmexa-Epimmune <i>San Diego, CA</i>	HIV-1 treatment	Phase I (858) 860-2500
EP-1232 (HIV vaccine polytope)	Pharmexa-Epimmune <i>San Diego, CA</i>	HIV infection prevention	Phase I (858) 860-2500
EP-2210 (hepatitis B DNA vaccine)	Pharmexa-Epimmune <i>San Diego, CA</i> Innogenetics <i>Alpharetta, GA</i>	hepatitis B treatment	Phase I (858) 860-2500 (888) 310-8788
eritoran (E5564)	Eisai <i>Ridgefield Park, NJ</i>	septic shock	Phase III (888) 274-2378
etravirine (TMC-125)	Tibotec Pharmaceuticals <i>Yardley, PA</i>	HIV infection treatment	application submitted (609) 730-7500
fozivudine tidoxil	Heidelberg Pharma <i>Ladenberg, Germany</i>	HIV infection treatment	Phase II www. heidelbergpharma.com
Fuzeon® enfuvirtide (needle-free injection)	Roche <i>Nutley, NJ</i> Trimeris <i>Morrisville, NC</i>	HIV-1 infection	Phase II (973) 235-5000 (919) 419-6050
GENEVAX (HIV DNA vaccine)	Wyeth Pharmaceuticals <i>Collegeville, PA</i>	HIV-1 infection	Phase I (800) 934-5556
GS-9160	Gilead Sciences <i>Foster City, CA</i>	HIV infection	Phase I (650) GILEAD-5
hepatitis B DNA vaccine	Pfizer <i>New York, NY</i> PowderMed <i>Oxford, UK</i>	hepatitis B treatment	Phase I (860) 732-5156
hepatitis B vaccine	GenPhar <i>Mount Pleasant, SC</i>	hepatitis B	Phase I (843) 884-0120
Heplisav™ hepatitis B vaccine	Dynavax Technologies <i>Berkeley, CA</i>	hepatitis B prevention	Phase II (510) 848-5100
HGTV-43™ (antisense therapy)	Enzo Therapeutics <i>Farmingdale, NY</i>	HIV-1 infection	Phase I (631) 755-5500
HIV attachment inhibitor	Bristol-Myers Squibb <i>Princeton, NJ</i>	HIV infection	Phase I (212) 546-4000

INFECTIOUS DISEASES

Product Name	Company	Indication	Development Status
HIV DNA vaccine (pGA2/JS2)	Emory University <i>Atlanta, GA</i> National Institutes of Health <i>Bethesda, MD</i>	HIV infection prevention	Phase I www.clinicaltrials.gov
HIV recombinant vaccine	GlaxoSmithKline <i>Philadelphia, PA</i> <i>Rsch. Triangle Park, NC</i>	HIV infection prevention	Phase I (888) 825-5249
HIV vaccine (VRC-HIV ADV-014)	GenVec <i>Gaithersburg, MD</i> NIH Vaccine Research Center <i>Bethesda, MD</i>	HIV infection prevention	Phase I/II (240) 632-0740
		HIV infection treatment	Phase I (240) 632-0740
HIV vaccine (VRC-HIV DNA-016)	Dale and Betty Bumpers Vaccine Research Center at the National Institutes of Health <i>Bethesda, MD</i>	HIV infection prevention	Phase II www.vrc.nih.gov
		HIV infection treatment	Phase I www.vrc.nih.gov
HIV vaccine	GeoVax <i>Atlanta, GA</i>	HIV infection prevention	Phase I (404) 727-0971
HIV vaccine	sanofi pasteur <i>Swiftwater, PA</i>	HIV infection prevention (Thailand)	Phase III (570) 839-4267
ibalizumab (TNX-355)	Tanox <i>Houston, TX</i>	HIV infection treatment	Phase II (713) 578-4000
Immunitin™ HE 2000	Hollis-Eden Pharmaceuticals <i>San Diego, CA</i>	HIV infection treatment	Phase II (858) 587-9333
INCB-9471	Incyte <i>Wilmington, DE</i>	HIV infection treatment	Phase II (302) 498-6700
INCB-15050	Incyte <i>Wilmington, DE</i>	HIV infection	Phase I (302) 498-6700
KP-1461	Koronis Pharmaceuticals <i>Redmond, WA</i>	HIV infection treatment	Phase I (425) 825-0240
Leukine® sargramostim	Bayer HealthCare Pharmaceuticals <i>Wayne, NJ</i>	HIV infection treatment (see also heart disease)	Phase III (888) 84-BAYER
maraviroc	Pfizer <i>New York, NY</i>	HIV infection treatment	application submitted (860) 732-5156
moxifloxacin	Bayer HealthCare Pharmaceuticals <i>Wayne, NJ</i> Global Alliance for TB Drug Development <i>New York, NY</i>	tuberculosis	Phase II (212) 227-7540

INFECTIOUS DISEASES

Product Name	Company	Indication	Development Status
Nabi-HB® hepatitis B immune globulin (intravenous)	Nabi Biopharmaceuticals <i>Boca Raton, FL</i>	hepatitis B prevention	application submitted (800) 635-1766
nonakine	Gryphon Therapeutics <i>South San Francisco, CA</i>	HIV infection treatment	Phase I (650) 952-7714
NOX-100	Medinox <i>Carlsbad, CA</i>	septic shock	Phase II (760) 603-8989
PA-824	Global Alliance for TB Drug Development <i>New York, NY</i>	tuberculosis	Phase I (212) 227-7540
PA-1050040	Panacos Pharmaceuticals <i>Watertown, MA</i>	HIV infection treatment	Phase I (617) 926-1551
PBS-119	Phoenix Biosciences <i>Hollywood, FL</i>	HIV infection treatment	Phase I (954) 963-6647
PEHRG-214	Virionyx <i>Auckland, New Zealand</i>	HIV-1 infection	Phase II www.virionyx.com
PF-232798	Pfizer <i>New York, NY</i>	HIV infection	Phase I (860) 732-5156
PF-03491390	Pfizer <i>New York, NY</i>	septic shock	Phase I (860) 732-5156
PHP	Curacyte <i>Leipzig, Germany</i>	septic shock	Phase III www.curacyte.com
PMX-622	Novartis Pharmaceuticals <i>East Hanover, NJ</i>	septic shock	Phase II (888) NOW-NOVA
pradefovir	Schering-Plough <i>Kenilworth, NJ</i>	hepatitis B	Phase II (908) 298-4000
PRO 140	Progenics Pharmaceuticals <i>Tarrytown, NY</i>	HIV infection treatment	Phase I (914) 789-2800
PRO 2000	Indevus Pharmaceuticals <i>Lexington, MA</i>	HIV infection prevention	Phase II (781) 861-8444
Quinvaxem™	Berna Biotech <i>Bern, Switzerland</i> Novartis Pharmaceuticals <i>East Hanover, NJ</i>	hepatitis B prevention	Phase III (888) NOW-NOVA
Racivir®	Pharmasset <i>Princeton, NJ</i>	HIV infection treatment	Phase II (609) 613-4100
raltegravir (MK-0518)	Merck <i>Whitehouse Station, NJ</i>	HIV-1 infection	application submitted (800) 672-6372
RDEA806	Ardea Biosciences <i>Carlsbad, CA</i>	HIV infection	Phase I (760) 602-8422
Segard™ afelimomab	Abbott Laboratories <i>Abbott Park, IL</i>	sepsis, septic shock	Phase III (847) 937-6100

INFECTIOUS DISEASES

Product Name	Company	Indication	Development Status
SP-01A	Samaritan Pharmaceuticals <i>Las Vegas, NV</i>	HIV infection treatment	Phase II (702) 735-7001
SQ-109	Sequella <i>Rockville, MD</i>	tuberculosis	Phase I (301) 762-7776
TAK-242	Takeda Pharmaceuticals North America <i>Deerfield, IL</i>	septic shock	Phase III (224) 554-6500
TBC-3B (HIV vaccine)	Therion Biologics <i>Cambridge, MA</i> National Institutes of Health <i>Bethesda, MD</i>	HIV-1 infection	Phase I (617) 475-7500
Thalomid® thalidomide	Celgene <i>Summit, NJ</i>	HIV infection treatment (see also cancer, lupus)	Phase II (908) 673-9000
		tuberculosis	in clinical trials (908) 673-9000
TNF-alpha inhibitor	Advanced Biotherapy <i>Chicago, IL</i>	HIV infection treatment	Phase I (312) 427-1912
UC-781	Biosyn <i>Huntingdon Valley, PA</i> Cellegy Pharmaceuticals <i>Huntingdon Valley, PA</i>	HIV infection prevention	Phase I (215) 914-0900
Ushercell® cellulose sulfate	Polydex Pharmaceuticals <i>Toronto, ON</i>	HIV infection prevention	Phase I (416) 755-2441
V520	Merck <i>Whitehouse Station, NJ</i>	HIV-1 infection	Phase II (800) 672-6372
V526	Merck <i>Whitehouse Station, NJ</i>	HIV infection	Phase II (800) 672-6372
valtorcitabine	Idenix Pharmaceuticals <i>Cambridge, MA</i> Novartis Pharmaceuticals <i>East Hanover, NJ</i>	hepatitis B	Phase II (617) 995-9800 (888) NOW-NOVA
VGX-410	VGX Pharmaceuticals <i>Blue Bell, PA</i>	HIV infection	Phase II (267) 440-4200
vicriviroc	Schering-Plough <i>Kenilworth, NJ</i>	HIV-1 infection	Phase II (908) 298-4000
Viread® tenofovir disoproxil fumarate	Gilead Sciences <i>Foster City, CA</i>	hepatitis B treatment	Phase III (800) GILEAD-5
VRX496 (gene therapy)	VIRxSYS <i>Gaithersburg, MD</i>	HIV infection treatment	Phase II (301) 987-0480
Zadaxin® thymalfasin	SciClone Pharmaceuticals <i>San Mateo, CA</i>	hepatitis B	Phase II (650) 358-3456

KIDNEY DISEASES

Product Name	Company	Indication	Development Status
alagebrium (ALT-711)	Alteon <i>Montvale, NJ</i>	renal failure (see also heart disease)	Phase I (201) 934-5000
Altace [®] ramipril	King Pharmaceuticals <i>Bristol, TN</i>	chronic kidney disease in hypertensive patients (see also diabetes)	application submitted (800) 776-3637
AST-120	Ocera Therapeutics <i>San Diego, CA</i>	renal failure	Phase III (858) 436-3900
avosentan	Speedel Pharmaceuticals <i>Princeton, NJ</i>	diabetic nephropathies	Phase III (732) 537-2290
belatacept	Bristol-Myers Squibb <i>Princeton, NJ</i>	kidney transplant rejection	Phase III (212) 546-4000
CellCept [®] mycophenolate mofetil	Aspreva Pharmaceuticals <i>Victoria, BC</i> Roche <i>Nutley, NJ</i>	lupus nephritis	Phase III (250) 744-2488 (973) 235-5000
Corlopam [®] intravenous fenoldopam	Elan Pharmaceuticals <i>New York, NY</i>	renal failure (see also heart disease)	Phase II (212) 407-5740
CR-002	Curagen <i>Branford, CT</i>	IgA nephropathy	Phase I (888) 436-6642
Diovan [®] valsartan	Novartis Pharmaceuticals <i>East Hanover, NJ</i>	diabetic nephropathies	Phase III (888) NOW-NOVA
farglitazar	GlaxoSmithKline <i>Philadelphia, PA</i> <i>Rsch. Triangle Park, NC</i>	hepatic fibrosis	Phase II (888) 825-5249
FG 3019	FibroGen <i>South San Francisco, CA</i>	diabetic nephropathies	Phase I (650) 866-7200
Fluimucil [®] acetylcysteine	Zambon <i>Rutherford, NJ</i>	renal failure	Phase II (201) 939-4800
Freedox [®] tirilazad	Pfizer <i>New York, NY</i>	kidney disease prevention (see also stroke)	Phase II (860) 732-5156
ilepatril (ACE/NEP inhibitor)	sanofi-aventis <i>Bridgewater, NJ</i>	diabetic nephropathies (see also heart disease)	Phase II (800) 633-1610
Lucassin [™] terlipressin intravenous	Orphan Therapeutics <i>Lebanon, NJ</i>	hepatorenal syndrome type 1	Phase III (908) 849-4805
PS-433540	Pharmacopeia Drug Discovery <i>Cranbury, NJ</i>	diabetic nephropathies (see also heart disease)	Phase I (609) 452-3600
Pyridorin [®] pyridoxamine	NephroGenex <i>Cary, NC</i>	diabetic nephropathies	Phase II (919) 678-9512
Renal Bio-Replacement Therapy [®]	RenaMed Biologics <i>Westborough, MA</i>	renal failure	Phase II

KIDNEY DISEASES

Product Name	Company	Indication	Development Status
Riquent [®] abetimus	La Jolla Pharmaceutical San Diego, CA	lupus nephritis	application submitted (858) 452-6600
Rituxan [®] rituximab	Biogen Idec Cambridge, MA Genentech South San Francisco, CA	lupus nephritis (see also lupus)	Phase III (617) 679-2000 (650) 225-1000
SLV-320	Solvay Pharmaceuticals Marietta, GA	kidney disorders (see also heart disease)	Phase II (770) 578-9000
Sulonex [™] sulodexide	Keryx Biopharmaceuticals New York, NY	diabetic nephropathies	Phase III (212) 531-5965
Tekturna [®] aliskiren	Novartis Pharmaceuticals East Hanover, NJ	diabetic nephropathies	Phase II (888) NOW-NOVA
tolvaptan (OPC-41061)	Otsuka America Pharmaceutical Rockville, MD	polycystic kidney disease (see also heart disease)	Phase II (800) 562-3974
TTPABC	TransTech Pharma High Point, NC	diabetic nephropathies	Phase I (336) 841-0300
urtoxazumab	Teijin America Princeton, NJ	hemolytic uremic syndrome	Phase I (609) 716-7636
XL784	Exelixis South San Francisco, CA	diabetic nephropathies	Phase II (650) 837-7000

LUNG/RESPIRATORY DISORDERS

Product Name	Company	Indication	Development Status
159797 (long-acting beta2 agonist)	GlaxoSmithKline Philadelphia, PA Rsch. Triangle Park, NC	asthma, chronic obstructive pulmonary disease (COPD)	Phase II (888) 825-5249
597901 (long-acting beta2 agonist)	GlaxoSmithKline Philadelphia, PA Rsch. Triangle Park, NC	asthma, COPD	Phase II (888) 825-5249
642444 (long-acting beta2 agonist)	GlaxoSmithKline Philadelphia, PA Rsch. Triangle Park, NC	asthma, COPD	Phase II (888) 825-5249
681323 (p38 kinase inhibitor, oral)	GlaxoSmithKline Philadelphia, PA Rsch. Triangle Park, NC	COPD	Phase II (888) 825-5249
799943 (glucocorticoid agonist)	GlaxoSmithKline Philadelphia, PA Rsch. Triangle Park, NC	asthma, COPD	Phase II (888) 825-5249
856553 (p38 kinase inhibitor, oral)	GlaxoSmithKline Philadelphia, PA Rsch. Triangle Park, NC	COPD	Phase II (888) 825-5249
ABN-912	Novartis Pharmaceuticals East Hanover, NJ	asthma, COPD	Phase I (888) NOW-NOVA

LUNG/RESPIRATORY DISORDERS

Product Name	Company	Indication	Development Status
acclidinium bromide	Forest Laboratories <i>New York, NY</i>	COPD	Phase III (800) 678-1605
AER-001	Aerovance <i>Berkeley, CA</i>	acute asthma	Phase II (510) 549-5500
AER-002	Aerovance <i>Berkeley, CA</i>	COPD	Phase II (510) 549-5500
Aerosurf [®] sinapultide	Discovery Laboratories <i>Warrington, PA</i>	asthma	Phase I (215) 488-9300
Allegra [®] fexofenadine (disintegrating tablets)	sanofi-aventis <i>Bridgewater, NJ</i>	asthma	application submitted (800) 633-1610
Alvesco [®] ciclesonide	Altana Pharma US (Nycomed) <i>Florham Park, NY</i>	asthma	application submitted (973) 514-4240
Alvesco [®] Combo ciclesonide/ formoterol	Altana Pharma US (Nycomed) <i>Florham Park, NY</i> sanofi-aventis <i>Bridgewater, NJ</i>	asthma	Phase II (973) 514-4240 (800) 633-1610
AMG 317	Amgen <i>Thousand Oaks, CA</i>	asthma	Phase I (800) 77-AMGEN
anti-interleukin-8 monoclonal antibody	Amgen <i>Thousand Oaks, CA</i> XenoTech <i>Lenexa, KS</i>	COPD	Phase II (805) 447-1000
Ariflo [®] cilomilast	GlaxoSmithKline <i>Philadelphia, PA</i> <i>Rsch. Triangle Park, NC</i>	COPD	application submitted (888) 825-5249
ASM 8	Topigen Pharmaceuticals <i>Montreal, QC</i>	asthma	Phase II (514) 868-0077
Augmentin [®] XR amoxicillin/ clavulanic acid controlled-release	GlaxoSmithKline <i>Philadelphia, PA</i> <i>Rsch. Triangle Park, NC</i>	acute exacerbations of chronic bronchitis	Phase III (888) 825-5249
AVE8923 (tryptase B inhibitor)	sanofi-aventis <i>Bridgewater, NJ</i>	asthma	Phase I (800) 633-1610
AVP-13358	Avanir Pharmaceuticals <i>Aliso Viejo, CA</i>	allergic asthma	Phase I (949) 389-6700
Azmacort HFA [®] triamcinolone acetone hydrofluoroalkane inhalation	Abbott Laboratories <i>Abbott Park, IL</i>	asthma	Phase III (847) 937-6100

LUNG/RESPIRATORY DISORDERS

Product Name	Company	Indication	Development Status
beclometasone hydrofluoroalkane inhalation	IVAX <i>Miami, FL</i>	asthma	Phase III (305) 575-6000
bedoradrine	MediciNova <i>San Diego, CA</i>	status asthmaticus	Phase II (858) 373-1500
BIW-8405	MedImmune <i>Gaithersburg, MD</i>	asthma	Phase I (301) 398-0000
budesonide inhalation	MAP Pharmaceuticals <i>Mountain View, CA</i>	asthma	Phase II (650) 386-3100
CHF-5188	Chiesi Pharmaceuticals <i>Rockville, MD</i>	asthma, COPD	Phase II (301) 424-2661
CS-003	Daiichi Sankyo <i>Parsippany, NJ</i>	asthma, COPD	Phase II (973) 359-2600
CS-615	Daiichi Sankyo <i>Parsippany, NJ</i>	asthma	Phase II (973) 359-2600
CTI02 (zileuton)	Critical Therapeutics <i>Lexington, MA</i>	asthma	Phase III (781) 402-5700
		----- COPD	in clinical trials (781) 402-5700
CVT-6883	CV Therapeutics <i>Palo Alto, CA</i>	asthma	Phase I (650) 384-8500
Daxas [®] roflumilast	Altana Pharma US <i>Florham Park, NJ</i>	asthma, COPD	Phase III
EPI-12323	EpiGenesis Pharmaceuticals <i>Cranbury, NJ</i>	asthma, COPD	Phase II (609) 409-6080
epinastine	Boehringer Ingelheim Pharmaceuticals <i>Ridgefield, CT</i>	asthma	Phase I (800) 243-0127
etiprednol	IVAX <i>Miami, FL</i>	asthma	Phase II (305) 575-6000
Exhale [®] Drug-Eluting Stent paclitaxel	Broncus Technologies <i>Mountain View, CA</i>	emphysema	in clinical trials (650) 428-1600
fandosentan	Pfizer <i>New York, NY</i>	COPD	Phase I (860) 732-5156
faropenem medoxomil	Replidyne <i>Louisville, CO</i>	acute exacerbations of chronic bronchitis	Phase III (303) 996-5500
Flutiform [™] formoterol/ fluticasone propionate fixed combination	Abbott Laboratories <i>Abbott Park, IL</i>	asthma	Phase III (847) 937-6100

LUNG/RESPIRATORY DISORDERS

Product Name	Company	Indication	Development Status
formoterol hydrofluoroalkane inhalation	Chiesi Pharmaceuticals Rockville, MD	asthma	Phase II (301) 424-2661
golimumab	Centocor Horsham, PA Medarex Princeton, NJ	asthma	Phase II (610) 651-6000 (609) 430-2880
HAE1	Genentech South San Francisco, CA	allergic asthma	Phase II (650) 227-1000
IMA-638	Wyeth Pharmaceuticals Collegeville, PA	asthma	Phase II (800) 934-5556
interleukin-4/13 trap	Regeneron Pharmaceuticals Tarrytown, NY	asthma	Phase I (914) 345-7400
INV-102	Inverseon San Francisco, CA	asthma	Phase II (415) 440-7400
isatoribine	Anadys Pharmaceuticals San Diego, CA	asthma	Phase I (858) 530-3600
Kineret [®] anakinra	Amgen Thousand Oaks, CA	asthma	Phase II (805) 447-1000
Levaquin [®] levofloxacin	Johnson & Johnson Pharmaceutical Research & Development Raritan, NJ	acute exacerbations of chronic bronchitis	application submitted (800) 817-5286
lumiliximab	Biogen Idec Cambridge, MA	allergic asthma	Phase II (617) 914-6524
MEDI-528	Genaera Plymouth Meeting, PA MedImmune Gaithersburg, MD	asthma	Phase I (610) 941-4020 (301) 398-0000
mepolizumab	GlaxoSmithKline Philadelphia, PA Rsch. Triangle Park, NC	severe asthma	Phase II (888) 825-5249
mometasone/ formoterol combination	Schering-Plough Kenilworth, NJ	asthma, COPD	Phase III (908) 298-4000
Nasonex [®] mometasone	Schering-Plough Kenilworth, NJ	COPD	application submitted (908) 298-4000
oglemilast	Forest Laboratories New York, NY	asthma, COPD	Phase II (800) 678-1605
olopatadine	Alcon Research Fort Worth, TX	asthma	Phase II (800) 862-5266
PB-008	Inflabloc Pharmaceuticals Salt Lake City, UT	asthma	Phase II (801) 464-6100

LUNG/RESPIRATORY DISORDERS

Product Name	Company	Indication	Development Status
PDE IV inhibitor	Merck <i>Whitehouse Station, NJ</i>	asthma, COPD	Phase I (800) 633-1610
PGX-100	ParinGenix <i>Tucson, AZ</i>	COPD	Phase II
PW-3101	IVAX <i>Miami, FL</i> Penwest Pharmaceuticals <i>Danbury, CT</i>	asthma	application submitted (305) 575-6000 (203) 796-3700
Qvar® Easi-Breathe® beclometasone breath-activated inhalation	IVAX <i>Miami, FL</i>	asthma	Phase III (305) 575-6000
Remicade® infliximab	Centocor <i>Horsham, PA</i>	asthma, COPD	Phase II (610) 651-6000
RWJ-58643	Johnson & Johnson Pharmaceutical Research & Development <i>Raritan, NJ</i>	asthma	Phase I (800) 817-5286
salbutamol dry-powder inhalation	Innovata <i>Nottingham, UK</i>	asthma	Phase II
Serevent® salmeterol MDI dose counter	GlaxoSmithKline <i>Philadelphia, PA</i> <i>Rsch. Triangle Park, NC</i>	asthma, COPD	Phase III (888) 825-5249
Singulair® montelukast	Merck <i>Whitehouse Station, NJ</i>	acute asthma	Phase III (800) 672-6372
SMP-028	Dainippon Sumitomo Pharma <i>Osaka, Japan</i>	asthma	Phase I
sodium cromoglicate (oral)	Emisphere Technologies <i>Tarrytown, NY</i>	asthma	Phase I (914) 347-2220
Symbicort® budesonide/ formoterol	AstraZeneca <i>Wilmington, DE</i>	COPD	Phase III (800) 236-9933
tacrolimus inhalation	Astellas Pharma US <i>Deerfield, IL</i>	asthma	Phase II (800) 727-7003
TBC-4746	Encysive Pharmaceuticals <i>Houston, TX</i>	asthma	Phase I (713) 796-8822
tetomilast	Otsuka America Pharmaceutical <i>Rockville, MD</i>	COPD	Phase II (800) 562-3974
TNX-650	Tanox <i>Houston, TX</i>	asthma	Phase I (713) 578-4000

LUNG/RESPIRATORY DISORDERS

Product Name	Company	Indication	Development Status
tofimilast	Pfizer New York, NY	asthma	Phase II (860) 732-5156
tretinoin	Roche Nutley, NJ	emphysema	in clinical trials (973) 235-5000
trospium chloride inhalation	Alkermes Cambridge, MA Indevus Pharmaceuticals Lexington, MA	COPD	Phase II (617) 494-0171 (781) 861-8444
Zenapax [®] daclizumab	PDL BioPharma Fremont, CA	asthma	Phase II (510) 574-1400
Zmax [®] azithromycin controlled-release	Pfizer New York, NY	acute exacerbations of chronic bronchitis	application submitted (860) 732-5156

LUPUS

Product Name	Company	Indication	Development Status
Actemra [™] tocilizumab	Roche Nutley, NJ	systemic lupus erythematosus	Phase I (973) 235-5000
AMG 623	Amgen Thousand Oaks, CA	systemic lupus erythematosus	Phase I (805) 447-1000
anti-interferon alpha	Genentech South San Francisco, CA	systemic lupus erythematosus	Phase I (650) 225-1000
atacept (TACI-Ig)	EMD Serono Rockland, MA ZymoGenetics Seattle, WA	systemic lupus erythematosus	Phase II (800) 283-8088 (800) 775-6686
belimumab	GlaxoSmithKline Philadelphia, PA Rsch. Triangle Park, NC Human Genome Sciences Rockville, MD	systemic lupus erythematosus	Phase III (888) 825-5249 (301) 309-8504
edratide (TV-4710)	Teva Pharmaceuticals USA North Wales, PA	systemic lupus erythematosus	Phase II (215) 591-3000
epratuzumab (IMMU-103)	Immunomedics Morris Plains, NJ UCB Smyrna, GA	systemic lupus erythematosus	Phase III (973) 605-8200 (770) 970-7500
ETI-201	Elusys Therapeutics Pine Brook, NJ	systemic lupus erythematosus	Phase I (973) 808-0222
MEDI-545	Medarex Princeton, NJ MedImmune Gaithersburg, MD	systemic lupus erythematosus	Phase I (609) 430-2880 (301) 398-0000

LUPUS

Product Name	Company	Indication	Development Status
Orencia [®] abatacept	Bristol-Myers Squibb <i>Princeton, NJ</i>	lupus	in clinical trials (212) 546-4000
Prestara [™] prasterone	Genelabs Technologies <i>Redwood City, CA</i> Watson Pharmaceuticals <i>Corona, CA</i>	systemic lupus erythematosus	Phase III (650) 369-9500 (800) 249-5499
Rituxan [®] rituximab	Biogen Idec <i>Cambridge, MA</i> Genentech <i>South San Francisco, CA</i>	systemic lupus erythematosus (see also kidney diseases)	Phase III (617) 679-2000 (650) 225-1000
Thalomid [®] thalidomide	Celgene <i>Summit, NJ</i>	systemic lupus erythematosus (see also cancer, infectious diseases)	in clinical trials (609) 673-9000

OBESITY

Product Name	Company	Indication	Development Status
189075 (sodium dependent glucose transport [SGLT2] inhibitor)	GlaxoSmithKline <i>Philadelphia, PA</i> <i>Rsch. Triangle Park, NC</i>	obesity (see also diabetes)	Phase II (888) 825-5249
AC-162352	Amylin Pharmaceuticals <i>San Diego, CA</i>	obesity	Phase I (858) 552-2200
Acomplia [®] rimonabant	sanofi-aventis <i>Bridgewater, NJ</i>	obesity (see also diabetes)	application submitted (800) 633-1610
AVE1625 (CB1 antagonist)	sanofi-aventis <i>Bridgewater, NJ</i>	obesity	Phase II (800) 633-1610
betahistine	Obecure <i>Ramat Gan, Israel</i>	obesity	Phase II www.obecure.com
CB-1 antagonist	Bristol-Myers Squibb <i>Princeton, NJ</i> Solvay Pharmaceuticals <i>Marietta, GA</i>	obesity	Phase II (212) 546-4000
CE-326597	Pfizer <i>New York, NY</i>	obesity	Phase I (860) 732-5156
cetilistat	Alizyme <i>Cambridge, UK</i>	obesity (see also diabetes)	Phase II www.alizyme.com
Contrave [™] naltrexone/ bupropion	Orexigen Therapeutics <i>San Diego, CA</i>	obesity	Phase III (858) 436-8600
Corlux [™] mifepristone	Corcept Therapeutics <i>Menlo Park, CA</i>	obesity (see also cancer)	Phase II (650) 327-3270
CP-741952	Pfizer <i>New York, NY</i>	obesity	Phase II (860) 732-5156

OBESITY

Product Name	Company	Indication	Development Status
CP-866087	Pfizer New York, NY	obesity	Phase I (860) 732-5156
CP-945598	Pfizer New York, NY	obesity	Phase III (860) 732-5156
Empatic [®] zonisamide/ bupropion	Orexigen Therapeutics San Diego, CA	obesity	Phase II (858) 436-8600
Glyset [®] miglitol	Pfizer New York, NY	obesity	Phase II (860) 732-5156
GT-389255	Peptimmune Cambridge, MA	obesity	Phase II (617) 715-8000
KD3010	Kalypsys San Diego, CA	obesity	Phase I (858) 754-3300
lorcaserin	Arena Pharmaceuticals San Diego, CA	obesity	Phase III (858) 453-7200
Micardis [®] telmisartan	Boehringer Ingelheim Pharmaceuticals Ridgefield, CT	obesity	Phase II (800) 243-0127
NGD-4715	Neurogen Branford, CT	obesity	Phase I (203) 488-8201
octreotide	Novartis Pharmaceuticals East Hanover, NJ	obesity	Phase II (800) NOW-NOVA
peptide YY3-36 intranasal	Nastech Pharmaceutical Bothell, WA	obesity	Phase I (425) 908-3600
PF-431499	Pfizer New York, NY	obesity	Phase I (860) 732-5156
PF-514273	Pfizer New York, NY	obesity	Phase I (860) 732-5156
PRX-07034	EPIX Pharmaceuticals Lexington, MA	obesity	Phase I (781) 761-7600
Qnexa [™] phentermine/ topiramate	VIVUS Mountain View, CA	obesity	Phase II (650) 934-5200
QRX-431	QuatRx Pharmaceuticals Ann Arbor, MI	obesity	Phase I (734) 913-9900
S-2367	Shionogi USA Florham Park, NJ	obesity	Phase II (973) 966-6900
second-generation amylin mimetic	Amylin Pharmaceuticals San Diego, CA	obesity	Phase I (858) 552-2200
sergliflozin	GlaxoSmithKline Philadelphia, PA Rsch. Triangle Park, NC	obesity	Phase II (888) 825-5249

OBESITY

Product Name	Company	Indication	Development Status
Symlin [®] pramlintide	Amylin Pharmaceuticals <i>San Diego, CA</i>	obesity	Phase II (858) 552-2200
taranabant (MK-0364)	Merck <i>Whitehouse Station, NJ</i>	obesity	Phase III (800) 672-6372
trodesquamine	Genaera <i>Plymouth Meeting, PA</i>	obesity	Phase I (610) 941-4020
Zoloft [®] sertraline	Pfizer <i>New York, NY</i>	obesity	in clinical trials (860) 732-5156
Zonegran [®] zonisamide	Eisai <i>Ridgefield Park, NJ</i>	obesity	Phase II (888) 274-2378

SICKLE CELL DISEASE

Product Name	Company	Indication	Development Status
ANGX-3227	Angiogenix <i>New York, NY</i>	sickle cell anemia	Phase II (212) 874-6608
Flocor [™] poloxamer 188 NF	CytRx <i>Los Angeles, CA</i> SynthRx <i>Houston, TX</i>	sickle cell anemia	Phase III (310) 825-5648
Kuvan [™] sapropterin	BioMarin Pharmaceutical <i>Novato, CA</i> EMD Serono <i>Rockland, MA</i>	sickle cell anemia (see also heart disease)	Phase II (415) 506-6700 (800) 283-8088

STROKE (CEREBROVASCULAR DISEASE)

Product Name	Company	Indication	Development Status
813893 (factor Xa inhibitor)	GlaxoSmithKline <i>Philadelphia, PA</i> <i>Rsch. Triangle Park, NC</i>	prevention of stroke in atrial fibrillation	Phase I (888)825-5249
apixaban (factor Xa inhibitor)	Bristol-Myers Squibb <i>Princeton, NJ</i> Pfizer <i>New York, NY</i>	prevention of stroke in atrial fibrillation (see also heart disease)	Phase III (212) 546-4000
argatroban	Encysive Pharmaceuticals <i>Houston, TX</i>	ischemic stroke (see also heart disease)	Phase II (713) 796-8822
Aricept [®] donepezil	Eisai <i>Ridgefield Park, NJ</i>	vascular dementia	application submitted (888) 274-2378
Arocyte [®] Injection arundic acid	Merck <i>Whitehouse Station, NJ</i>	acute ischemic stroke	Phase II (800) 672-6372
Cerebril [™] tramiprosate	Neurochem <i>Lavel, QC</i>	prevention of hemorrhagic stroke caused by cerebral amyloid angiopathy	Phase II (450) 680-4500

STROKE (CEREBROVASCULAR DISEASE)

Product Name	Company	Indication	Development Status
clazosentan	Actelion Pharmaceuticals US <i>South San Francisco, CA</i>	cerebral vasospasm	Phase II (650) 624-6900
desmoteplase	Forest Laboratories <i>New York, NY</i> Paion <i>Aachen, Germany</i>	acute ischemic stroke	Phase III (800) 947-5227
E2051	Eisai <i>Ridgefield Park, NJ</i>	cerebral infarction	Phase I (888) 274-2378
Exelon [®] rivastigmine	Novartis Pharmaceuticals <i>East Hanover, NJ</i>	vascular dementia	Phase III (888) NOW-NOVA
Freedox [®] tirilazad	Pfizer <i>New York, NY</i>	subarachnoid hemorrhage (see also kidney diseases)	application submitted (860) 732-5156
MC-1	Medicure <i>Winnipeg, Manitoba</i>	stroke (see also heart disease)	Phase I (888) 435-2220
MK-0724	Merck <i>Whitehouse Station, NJ</i>	stroke	Phase II (800) 672-6372
NA-1	Arbor Vita <i>Sunnyvale, CA</i>	stroke	Phase I (408) 585-3900
Nectiv [™] traxoprodil	Pfizer <i>New York, NY</i>	acute stroke	Phase II (860) 732-5156
NEU-2000	Amkor Pharma <i>Seattle, WA</i>	stroke (see also heart disease)	Phase I (206) 332-5587
piclozotan	Asubio Pharmaceuticals <i>Rochelle Park, NJ</i>	stroke	Phase II (201) 368-5020
Reminyl [®] galantamine	Johnson & Johnson Pharmaceutical Research & Development <i>Raritan, NJ</i>	vascular dementia	Phase III (800) 817-5286
Revoxyn [™]	Integra Life Sciences <i>Plainsboro, NJ</i>	stroke	Phase II (609) 936-2239
rivaroxaban	Bayer HealthCare Pharmaceuticals <i>Wayne, NJ</i> Johnson & Johnson Pharmaceutical Research & Development <i>Raritan, NJ</i>	stroke (see also heart disease)	Phase III (888) 84-BAYER (800) 817-5286
SUN N8075	Asubio Pharmaceuticals <i>Rochelle Park, NJ</i>	acute stroke	Phase I (201) 368-5020
TS-011	Taisho Pharmaceutical R&D <i>Morristown, NJ</i>	stroke	Phase I
V10153	Vernalis Pharmaceuticals <i>Morristown, NJ</i>	stroke (see also heart disease)	Phase II (888) 376-2547

STROKE (CEREBROVASCULAR DISEASE)

Product Name	Company	Indication	Development Status
Viprinex™ ancrod	Neurobiological Technologies Emeryville, CA	acute ischemic stroke	Phase III (510) 595-6000
zonampanel	Astellas Pharma US Deerfield, IL	acute ischemic stroke	Phase II (800) 695-4321

The content of this report has been obtained through public, government and industry sources, and the Adis "R&D Insight" database based on the latest information. **Report current as of July 19, 2007.** The information in this report may not be comprehensive. For more specific information about a particular product, contact the individual company directly or go to www.clinicaltrials.gov. The entire series of *Medicines in Development* is available on PhRMA's web site.

A publication of PhRMA's Communications & Public Affairs Department. (202) 835-3460

www.phrma.org | www.innovation.org | www.pparx.org | www.buysafedrugs.info | www.nuestraphrma.org

Provided as a Public Service by PhRMA. Founded in 1958 as the Pharmaceutical Manufacturers Association.

Copyright © 2007 by the Pharmaceutical Research and Manufacturers of America. Permission to reprint is awarded if proper credit is given.

acute coronary syndrome—A group of signs or symptoms that indicate insufficient blood flow to the heart muscle—as in heart attack, angina or chest pain or other symptoms.

application submitted—An application for marketing has been submitted by the company to the Food and Drug Administration.

asthma—Recurrent attacks of breathlessness and wheezing caused by a narrowing of the airways (bronchioles) leading to the lungs.

chronic obstructive pulmonary disease (COPD)—The combination of chronic bronchitis and emphysema, in which there is a persistent disruption of airflow out of the lungs and eventual hypoxemia (low levels of oxygen in the blood).

coronary artery disease—Caused by atherosclerosis of the arteries that supply the heart. Heart attacks and congestive heart failure result from coronary artery disease.

diabetes—A chronic disease due to a disturbance of the normal insulin mechanism causing problems in metabolizing sugar. Symptoms may include excessive thirst, hunger, urination and weight loss. Type 1 is the more severe form, requiring insulin treatment. Type 2, in most cases, can be controlled by a combination of dietary measures, weight loss and oral medication.

diabetic nephropathy—A complication in which the kidneys lose the ability to function properly. The condition is characterized by high protein levels in the urine. High blood pressure often accompanies diabetic nephropathy. Over time, the kidneys' ability to function starts to decline. Diabetic nephropathy may eventually lead to chronic kidney failure. The disorder continues to progress toward end-stage kidney

disease, often within two to six years after the appearance of high protein in the urine (proteinuria).

emphysema—An enlargement of the tiny air sacs of the lungs (alveoli) and the destruction of their walls, which causes structural and permanent narrowing of airflow.

glaucoma—An eye disease associated with increased pressure within the eyeball. If untreated, it may lead to permanent and complete blindness.

heart attack—The popular term for myocardial infarction, in which a part of the heart muscle (myocardium) dies as a result of blood and oxygen deprivation.

heart failure—The end result of many different types of heart disease. The heart cannot pump blood out normally. This results in congestion (water and salt retention) in the lungs, swelling in the extremities, and reduced blood flow to body tissues.

hepatitis B—Inflammation of the liver caused by hepatitis B virus (HBV). It can cause lifelong infection, cirrhosis (scarring) of the liver, liver cancer, liver failure, and death.

HIV infection—Presence of antibodies to the human immunodeficiency virus (the virus that causes AIDS) in the blood.

hypertension—An unstable or persistent elevation of blood pressure above the normal range while the heart is in systolic (contracting) or diastolic (relaxed) mode. Uncontrolled, chronic high blood pressure strains the heart, damages arteries and creates a greater risk of heart attack, stroke and kidney problems.

nephritis—Inflammation of one or both kidneys caused by infection, abnormal responses of the immune system and by metabolic disorders, such as gout.

obesity—The accumulation of excessive body fat. Generally, people whose weight is 20 percent or more over the midpoint of their weight range on a standard height-weight table are considered obese.

Phase I—Safety testing and pharmacological profiling of new drugs in small numbers of humans.

Phase II—Effectiveness testing and identification of side effects of new drugs in humans.

Phase III—Extensive clinical trials in humans to verify effectiveness and monitor adverse reactions of new drugs.

pulmonary arterial hypertension—High blood pressure in the arteries supplying the lungs due to increased resistance to blood flow through the lungs.

renal failure—Chronic renal failure is a gradual and progressive loss of the ability of the kidneys to excrete wastes, concentrate urine, and conserve electrolytes. Unlike acute renal failure with its sudden, reversible failure of kidney function, chronic renal failure slowly gets worse. It most often results from any disease that causes gradual loss of kidney function. It can range from mild dysfunction to severe kidney failure. Progression may continue to end-stage renal disease (ESRD).

reperfusion ischemic damage—Reperfusion injury (the formation of highly reactive forms of oxygen) can result from a decrease or lack of oxygen (ischemia).

septic shock—Septic shock is a serious condition that occurs when an overwhelming infection leads to low blood pressure and low blood flow. The brain, heart, kidneys, and liver may not work properly or may fail. Any type of bacteria can cause

GLOSSARY

septic shock. Fungi and (rarely) viruses may also cause the condition.

sickle cell disease—An inherited, chronic and severe blood disease where the red blood cells are abnormal (sickle shaped), resulting in reduced oxygen-carrying capacity of the blood. The disease affects primarily African Americans.

stroke—Usually caused by atherosclerosis. A blood clot obstructs a

major blood vessel of the brain, resulting in death or serious brain damage, such as paralysis or loss of speech.

systemic lupus erythematosus—A chronic autoimmune disorder, affecting many systems of the body, including the kidneys and brain.


tuberculosis—An infectious disease caused by the organism *Mycobacterium tuberculosis*, which is

passed from person to person by breathing in airborne droplets (from coughing or sneezing). The bacteria multiply in the lungs and in some cases can spread to the lymph nodes. A person's immune system most frequently will attack and heal the infection, causing a scar on the lung.


MORE THAN 1,000 MEDICINES IN DEVELOPMENT FOR THE THREE LEADING CAUSES OF DEATH FOR AFRICAN AMERICANS

The three leading causes of death among African Americans—heart disease, cancer and stroke—are the focus of two recent reports by the Pharmaceutical Research and Manufacturers of America (PhRMA). The reports, *Medicines in Development for Heart Disease and Stroke* and *Medicines in Development for Cancer*, list medicines in development for several types of heart disease and cancer. Following are summaries of those medicines by category listed in each of those reports. The PhRMA surveys are all available at www.phrma.org.

MEDICINES IN DEVELOPMENT FOR HEART DISEASE AND STROKE



MEDICINES/VACCINES IN DEVELOPMENT FOR CANCER



SELECTED FACTS ABOUT AFRICAN AMERICANS AND DISEASE

10 Leading Causes of Death in African Americans, 2003 (Both sexes, all ages)

- | | |
|--|---|
| 1. Heart Disease (77,372) | 6. Assault (homicide) (8,392) |
| 2. Cancer (62,660) | 7. Nephritis (7,855) |
| 3. Cerebrovascular Diseases (18,806) | 8. Chronic Lower Respiratory Diseases (7,709) |
| 4. Diabetes Mellitus (12,892) | 9. HIV Infection/AIDS (7,479) |
| 5. Accidents (unintentional injuries) (12,351) | 10. Septicemia (6,206) |

Source: National Center for Health Statistics, *Deaths: Leading Causes for 2003*. National Vital Statistics Reports, Vol. 55, No. 10, March 15, 2007. (Note: Number in parentheses is the number of deaths in 2003.)

Cancer

- African Americans are more likely to develop and die from **cancer** than any other racial or ethnic population. The death rate from cancer among African-American males is about 38 percent higher than among white males; for African-American females, it is about 17 percent higher. African Americans have a higher mortality rate than whites for each of the major cancer sites (**colorectal, male lung, female breast, and prostate**), as well as higher incidence rates for all of these cancers, except female breast.¹
 - In 2003, African-American men were 1.4 times as likely to have new cases of **lung** and **prostate cancer**, as compared to non-Hispanic white men, and their five-year survival rates were also lower than the rates for white men. In 2004, African-American men were 2.4 times as likely to die from prostate cancer, as compared to non-Hispanic white men.²
 - In 2003, African-American women were 10 percent less likely than non-Hispanic white women to have been diagnosed with **breast cancer**, however, they were 35 percent more likely to die from the disease.²
-

Diabetes

- Some 13.3 percent of African Americans age 20 and older (3.2 million) have **diabetes**; however, one-third of them do not know they have it. African Americans are nearly two times more likely to have diabetes than whites.³
 - One in four African-American women over age 55 has **diabetes**, and 25 percent of all African Americans between the ages of 65 and 74 have the disease.³
 - Women in minority racial and ethnic groups are the hardest hit by **type 2 diabetes**—the prevalence is two to four times higher among African-American, Hispanic, American Indian, and Asian-Pacific Islander women than among white women.⁴
-

Glaucoma

- **Glaucoma** affects more than 2.2 million Americans age 40 and older, or about 1.9 percent of that population. In general, glaucoma is more common in African Americans, Hispanics, and the elderly. Glaucoma appears to be more common initially in women, but by age 65, prevalence becomes more comparable between the sexes. In the 65-69 age group, the prevalence rate for white females is about 1.6 percent, while in African-American females the rate is three times higher at 4.8 percent. For those age 80 and older, glaucoma affects more than 10 percent of African-American men and Hispanic women.⁵
-

Heart Disease/Hypertension

- **Cardiovascular disease (CVD)**, primarily **heart disease** and **stroke**, causes more deaths in Americans of both genders and all racial and ethnic groups than any other disease. It is also one of the leading causes of disability in the United States. Overall, minority and low-income populations have a disproportionate burden of death and disability from CVD.⁴
- Among non-Hispanic blacks age 20 and older, nearly 45 percent of men and 49 percent of women have **CVD**. In 2004, CVD caused the deaths of 47,476 black men and 53,513 black women. In 2001, the proportion of premature deaths (occurring before age 65) from CVD was greatest among American Indians and Alaska Natives (36 percent) and African Americans (31.5 percent) and lowest among whites (14.7 percent).⁶

SELECTED FACTS ABOUT AFRICAN AMERICANS AND DISEASE

Heart Disease/Hypertension (continued)

- The annual rates per 1,000 population of new **heart attacks (myocardial infarctions)** or **coronary heart disease (CHD)** deaths in African-American men are: 21.6 for ages 65-74, 27.9 for ages 75-84, and 57.1 for age 85 and older. For African-American women, those rates are: 8.6 for ages 65-74, 17.6 for ages 75-84, and 24.8 for age 85 and older. In 2004, CHD caused the deaths of 22,861 black males and 23,604 black females.⁶
 - The annual rates per 1,000 population of African-American men for new and recurrent **heart failure** events are: 21.1 for ages 65-74, 52 for ages 75-84, and 66.7 for age 85 and older. For African-American women, those rates are: 18.9 for ages 65-74, 33.5 for ages 75-84, and 48.4 for age 85 and older. In 2004, heart failure caused the deaths of 2,119 black men and 3,017 black women.⁶
 - The prevalence of **high blood pressure (HBP)** in African Americans is among the highest in the world, and it is increasing. Compared with whites, blacks develop HBP earlier in life, and their average blood pressures are much higher. As a result, compared with whites, blacks have a 1.3 times greater rate of **nonfatal stroke**, a 1.8 times greater rate of **fatal stroke**, a 1.5 times greater rate of **heart disease death**, and a 4.2 times greater rate of **end-stage renal disease**.⁶
 - Among African Americans age 20 and older, 42.6 percent of men and 46.6 percent of women have **HBP**. In 2004, HBP caused the deaths of 5,602 black males and 6,592 black females.⁶
-

Infectious Diseases

- **Hepatitis b** disproportionately affects African Americans. In 2003, among those ages 19-24, there were 15.9 cases of hepatitis b per 100,000 African Americans compared with 5.9 cases per 100,000 non-Hispanic whites. For the age group 25-39, the rate for African Americans was 20.9 compared with 7.7 for non-Hispanic whites. For those over age 40, the rate for African Americans was 11.2 and for whites, it was 3.3.²
- Of all racial and ethnic groups in the United States, **HIV and AIDS** have hit African Americans the hardest. Even though the estimated number of **HIV/AIDS** cases decreased among African Americans from 2001 through 2005, they still accounted for 49 percent of all HIV/AIDS cases diagnosed in 2005. That year, the rates of HIV/AIDS cases were 71.3 per 100,000 in the black population, 27.8 per 100,000 in the Hispanic population, and 8.8 per 100,000 in the white population.⁴
- **HIV/AIDS** affects African American children the most. In 2005, 104 (63 percent) of the 166 children under the age of 13 diagnosed with HIV/AIDS in 33 states were black.⁴
- During 2005, 41 percent of men and 64 percent of women living with **HIV/AIDS** were African American.⁴
- From 2001 through 2005, the estimated number of **AIDS** cases increased among all racial and ethnic groups. In 2005, rates of AIDS cases were 54.1 per 100,000 African Americans, 18 per 100,000 Hispanics, and 5.9 per 100,000 whites. At the end of 2005, an estimated 421,873 people were living with AIDS—44 percent were African American, 35 percent white, 19 percent Hispanic, and about 1 percent each for Asian/Pacific Islander and American Indian/Alaska Native.⁴
- In 2005, the rate of **AIDS** diagnoses for black adults and adolescents was 10 times the rate for whites and nearly three times the rate for Hispanics. The rate of AIDS diagnoses for black women was nearly 23 times the rate for white women. The rate of AIDS diagnoses for black men was eight times the rate for white men.⁴
- From 2001 through 2005, the estimated number of deaths of people with **AIDS** decreased among African Americans. From the beginning of the AIDS epidemic through December 2005, an estimated 211,559 African Americans with AIDS had died.⁴
- Non-Hispanic black people have a disproportionate share of **tuberculosis (TB)** in the United States. In 2004, TB was reported in 4,066 non-Hispanic blacks—28 percent of all people reported with TB nationally. That year, the rate of TB in non-Hispanic blacks was 11.3 cases per 100,000 population—more than eight times higher than the rate of TB in non-Hispanic whites (1.3 cases per 100,000).⁴

SELECTED FACTS ABOUT AFRICAN AMERICANS AND DISEASE

Kidney Diseases⁷

- African Americans are nearly four times more likely compared with Caucasians to develop **kidney failure**, which requires dialysis or a kidney transplant. African Americans account for 32 percent of people with kidney failure.
 - Among new patients whose **kidney failure** was caused by **high blood pressure**, more than half (51.2 percent) are African American. African-American men ages 20 to 29 are 10 times more likely to develop kidney failure due to high blood pressure than Caucasian men in the same age group. In the 30-39 age group, African-American men are 14 times more likely than Caucasian men to develop kidney failure due to high blood pressure.
 - Among new patients whose **kidney failure** was caused by **diabetes**, almost one-third (31.3 percent) are African American.
-

Lung/Respiratory Disorders⁸

- African Americans have the highest **asthma** rates than any other racial/ethnic group. In 2002, the asthma prevalence rate in African Americans was almost 38 percent higher than among whites. The prevalence rate was also 95 percent higher in African Americans than in Hispanics.
 - In 2002, an estimated 4.8 million African Americans had been diagnosed with **asthma** in their lifetime: 3.4 million of them currently have asthma, and 2 million said they experienced an asthma attack in the past year.
 - In 2001, African Americans were three times more likely to be hospitalized for **asthma** than whites and five times more likely to seek care at an emergency room.
 - African Americans also have higher rates of **asthma mortality**. In 2001, African Americans were three times more likely to die from asthma than were whites.
 - Historically, African Americans have had lower **chronic bronchitis** prevalence rates than whites; however, in 2002, chronic bronchitis rates among African Americans were slightly higher than the rates among whites for the first time. That year, 7.6 million whites (45.7 per 1,000) and 1.1 million African Americans (46.1 per 1,000) had chronic bronchitis.
 - The prevalence of **chronic obstructive pulmonary disease (COPD)** among African Americans is lower than that among whites. In 2002, 2.9 million whites (17.7 per 1,000) and close to 0.2 million African Americans (8.3 per 1,000) had **emphysema**.
 - The **COPD** age-adjusted death rate in African Americans was 27.3 per 100,000 in 2001, which was 60 percent less than the rate among whites. African-American men had an age-adjusted death rate that was 21 percent less than that in white men, while African-American women were half as likely to die from COPD as were white women. Although African Americans have lower prevalence and mortality rates than whites, they tend to have higher rates of hospitalization and emergency room visits and similar disease severity at an earlier age compared with white COPD patients.
-

Lupus⁴

- **Lupus** affects an estimated 239,000 people in the United States, and about nine out of 10 are women. Lupus is three times more common in black women than in white women. Black and Hispanic women tend to develop symptoms at an earlier age than other women. And African-American women have more severe organ problems, especially with their kidneys.
 - Between 1979 and 1998, death rates from **lupus** increased nearly 70 percent among African-American women between the ages of 45 and 64. Each year during the study period, death rates were more than five times higher for women than for men and more than three times higher for blacks than for whites.
-

Obesity

- Studies show that 79.6 percent of non-Hispanic black women and 67 percent of non-Hispanic black men who are age 20 or older are **overweight** or **obese**, leaving them at higher risk for **heart disease**, **stroke**, gallstones, and degenerative joint disease.⁶

SELECTED FACTS ABOUT AFRICAN AMERICANS AND DISEASE

Sickle Cell Disease

- **Sickle cell anemia** is the most common inherited blood disorder in the United States, affecting about 72,000 Americans or 1 in 500 African Americans. About 8 percent of the African-American population are carriers.⁹ Each year, about 1 in 600 African Americans is born with sickle cell disease.¹⁰
-

Stroke (Cerebrovascular Disease)⁶

- African Americans have almost twice the risk of first-ever **stroke** compared with whites. The age-adjusted stroke incidence rates (per 100,000) for first-ever strokes are 323 for black males and 260 for black females. Among African-Americans age 20 and older, 4.1 percent of both men and women have had a stroke.
 - Between 1980 and 1999, the hospital discharge rates for **stroke** increased for African Americans and whites, while the in-hospital mortality rates decreased for both black and white patients. Generally, the risk of a stroke hospitalization was more than 70 percent greater for blacks than for whites.
 - In 2004, **strokes** caused the deaths of 7,555 African-American males and 10,373 African-American females.
-

Sources:

1. American Cancer Society (www.cancer.org)
2. Office of Minority Health, U.S. Department of Health and Human Services (www.omhrc.gov)
3. American Diabetes Association (www.diabetes.org)
4. Centers for Disease Control and Prevention, U.S. Department of Health and Human Services (www.cdc.gov)
5. Prevent Blindness America (www.preventblindness.org)
6. American Heart Association (www.americanheart.org)
7. National Kidney Disease Education Program (NKDEP). NKDEP is an initiative of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH), U.S. Department of Health & Human Services (DHHS) (www.nkdep.nih.gov)
8. American Lung Association (www.lungusa.org)
9. National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health (www.ncbi.nlm.nih.gov)
10. The National Women's Health Information Center, U.S. Department of Health and Human Services, Office of Women's Health (www.4women.gov)

THE DRUG DISCOVERY, DEVELOPMENT AND APPROVAL PROCESS

It takes 10-15 years on average for an experimental drug to travel from the lab to U.S. patients. Only five in 5,000 compounds that enter preclinical testing make it to human testing. One of these five tested in people is approved.

Discovery/ Preclinical Testing		Clinical Trials			FDA	Phase IV
		Phase I	Phase II	Phase III		
Years	6.5	1.5	2	3.5	1.5	
Test Population	Laboratory and animal studies	20 to 100 healthy volunteers	100 to 500 patient volunteers	1,000 to 5,000 patient volunteers	Review process/ approval	Additional post- marketing testing required by FDA
Purpose	Assess safety, biological activity and formulations	Determine safety and dosage	Evaluate effectiveness, look for side effects	Confirm effectiveness, monitor adverse reactions from long-term use		
Success Rate	5,000 compounds evaluated	5 enter trials			1 approved	

THE DRUG DEVELOPMENT AND APPROVAL PROCESS

The U.S. system of new drug approvals is perhaps the most rigorous in the world.

It takes 10-15 years, on average, for an experimental drug to travel from lab to U.S. patients, according to the Tufts Center for the Study of Drug Development, based on drugs approved from 1994 through 1998. Only five in 5,000 compounds that enter preclinical testing make it to human testing. And only one of those five is approved for sale.

On average, it costs a company \$802 million to get one new medicine from the laboratory to U.S. patients, according to a November 2001 report by the Tufts Center for the Study of Drug Development.

Once a new compound has been identified in the laboratory, medicines are developed as follows:

Preclinical Testing. A pharmaceutical company conducts laboratory and animal studies to show biological activity of the compound against the targeted disease, and the compound is evaluated for safety.

Investigational New Drug Application (IND). After completing preclinical testing, a company files an IND with the U.S. Food and Drug Administration (FDA) to begin to test the drug in people. The IND becomes effective if FDA does not disapprove it within 30 days. The IND shows results of previous experiments; how, where and by whom the new studies will be conducted; the chemical structure of the compound; how it is thought to work in the body; any toxic effects found in the animal studies; and how the compound is manufactured. All clinical trials must be reviewed and approved by the Institutional Review Board (IRB) where the trials will be conducted. Progress reports on clinical trials must be submitted at least annually to FDA and the IRB.

Clinical Trials, Phase I. These tests involve about 20 to 100 normal, healthy volunteers. The tests study a drug's safety profile, including the safe dosage range. The studies also determine how a drug is absorbed, distributed, metabolized, and excreted as well as the duration of its action.

Clinical Trials, Phase II. In this phase, controlled trials of approximately 100 to 500 volunteer patients (people with the disease) assess a drug's effectiveness.

Clinical Trials, Phase III. This phase usually involves 1,000 to 5,000 patients in clinics and hospitals. Physicians monitor patients closely to confirm efficacy and identify adverse events.

New Drug Application (NDA)/Biologic License Application (BLA). Following the completion of all three phases of clinical trials, a company analyzes all of the data and files an NDA or BLA with FDA if the data successfully demonstrate both safety and effectiveness. The applications contain all of the scientific information that the company has gathered. Applications typically run 100,000 pages or more. The average review time for the 29 new therapeutics approved by the FDA in 2006 was 15.6 months.

Approval. Once FDA approves an NDA or BLA, the new medicine becomes available for physicians to prescribe. A company must continue to submit periodic reports to FDA, including any cases of adverse reactions and appropriate quality-control records. For some medicines, FDA requires additional trials (Phase IV) to evaluate long-term effects.

Discovering and developing safe and effective new medicines is a long, difficult, and expensive process. PhRMA member companies invested an estimated \$43 billion in research and development in 2006.

To Assure Full Benefits from Medicines, African Americans Should Participate in Appropriate Clinical Trials

BY NELSON ADAMS, M.D.

PRESIDENT, NATIONAL MEDICAL ASSOCIATION

The 691 medicines being tested for major diseases affecting African Americans provide good news for all black families. Even better is that the pharmaceutical industry, like the National Medical Association, is working to recruit more minorities to participate in clinical trials of new medicines.

We know that people respond to medications in various ways. Some of the differences are due in part to genetic makeup and ethnicity. Unless African Americans are well represented in the clinical trials of new medicines, their illnesses will be treated with medicines proven safe and effective only among white patients. Medicines tested on people of one racial or ethnic group may not be as effective when taken by another racial or ethnic group. To ensure that medicines will be effective when administered to black patients, it's important for African Americans to participate in appropriate clinical trials.

What are clinical trials? Why are they conducted? What information is available? And why is it important for African Americans to participate?

Before a prescription medicine is approved by the U.S. Food and Drug Administration, the company that wants to market the drug has to prove that it's safe and effective. This involves trials of 1,000 and 3,000 or more human volunteers. Without clinical trials, no new medicines would be available to patients.

Before the medicine is tried in humans, it has already been tested for safety in the laboratory. Patients who participate in a clinical trial are informed of any known risks associated with the experimental medicine and are required to sign an informed consent document prior to participating in the trial. This document outlines

the patient's rights and responsibilities, as well as the obligations the sponsor of the trial has to the patient. It is ultimately up to the patient to decide whether a clinical trial is appropriate for their participation based on the potential benefits to them and to others like them, and their understanding of whether their rights and safety are being protected. Any volunteer may leave the trial at any time.

The potential benefits of participating in a clinical trial can be substantial. Patients are closely monitored. In addition to receiving special medical care, clinical trial patients get an opportunity to receive medicines before they are available to the general public—medicines that could potentially save or improve their lives.

Of course, not every patient who enters a clinical trial may actually be given the new medicine being studied. In many trials, there is a "control group" that takes either a placebo (a pill with no active ingredient) or the standard medicine currently used for the condition under study. However, if it's a major illness and the new medicine proves clearly beneficial and effective among those actually receiving the new medicine, researchers will often stop the trial and offer the new medicine to the control group, too.

In every clinical trial a question is being asked, such as: "What is the best way to treat or to avoid this disease?" To help determine the answer for African Americans, we need more African American volunteers.

For more information on clinical trials and the drug development and approval process, please see page 55 in this report. To get additional information on how to decide whether a clinical trial is appropriate for you, visit www.NMAnet.org and www.clinicaltrials.gov.



Pharmaceutical Research and Manufacturers of America
950 F Street, NW
Washington, DC 20004

www.phrma.org | www.innovation.org | www.pparx.org | www.buysafedrugs.info | www.nuestraphrma.org

9/07